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Abstract
The present study was designed to investigate the expression and function of an orphan 
seven transmembrane receptor named CCRL2 (CC chemokine receptor like 2), a 
putative chemokine receptor. In human tissues CCRL2 was expressed mainly by lung, 
lymphoid tissues and fetal spleen. Among leukocytes CCRL2 was expressed by 
monocytes, neutrophils and dendritic cells (DC). Because chemokines play a 
fundamental role in DC trafficking, modulation of CCLR2 expression in this cell type 
was further investigated. Maturative stimuli like LPS and CD40L strongly up regulated 
CCRL2 mRNA and protein in DC. Culture of DC in the presence of inhibitors of 
maturation and function such as VitD3 and Dex had no effect on LPS-induced CCRL2 
up regulation. On the contrary PGE2, that does not affect DC maturation, completely 
abolished LPS induction of CCRL2 expression. The effect of LPS and CD40L on 
CCRL2 expression was rapid (1.5h) and transient (maximal at 4h) and declined by 24h, 
conversely the upregulation of CCR7 that was slower and reached a plateau at 24h of 
stimulation.
Since CCRL2 gene is located in the main chemokine receptor cluster in the 3p21 
chromosome, it is likely to be a conventional inflammatory chemokine receptor. In 
order to identify ligands CCRL2 transfectants were used in chemotaxis and calcium flux 
assays with a broad panel of inflammatory CC and CXC chemokines but no ligand was 
identified. The alterations in the DRYLAR/IV motif in the second intracellular loop 
suggest that CCRL2 may be a candidate for the family of chemokine decoy receptors 
like the receptor D6. This second hypothesis was evaluated performing chemokine 
scavenging assays. None of the chemokine tested was scavenged by CCRL2. However 
in parallel experiments two new ligands for D6, the CCR4 agonists CCL17 and CCL22 
were identified. In summary these data suggest that CCRL2 might be involved in DC 
trafficking, through the regulation of the DC emigration from tissues following
stimulation. None of the chemokine tested was able to bind or activate CCRL2. 
Furthermore CCRL2 appears not to act as a chemokine scavenger receptor and its 
biological role is still elusive.
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Chapter 1-Introduction
1 C h a p t e r  1
1.1 Dendritic cells
1.1.1 Introduction
Dendritic cells (DC) are the most potent antigen-presenting cell in the immune system 
because they have unique capacity in capturing and processing antigens for presentation 
to T cells and because they express high levels of the co-stimulatory molecules for T- 
cell activation (1, 2). In addition to efficiently inducing the activation and proliferation 
of naive T cells, they fine-tune immune responses by instructing T-cell differentiation 
and polarization. DC transmit a distinct set of instructions to T cells that is based on 
their state of differentiation or maturation, and these instructions programme outcomes 
that range from humoral to cytolytic to suppressive (regulatory) T-cell responses (3).
Paul Langerhans in 1868 first described dendritic cells (DC) in human skin but thought 
these were cutaneous nerve cells. Steinman and Cohn (4) discovered these cells almost a 
century later in mouse spleen and called them "dendritic cells" on the basis of their 
unique morphology. Progress in the study of DC biology exploded in the 1990s when 
investigators developed cytokine-driven methods for expanding and differentiating DC 
ex vivo in both mouse and human systems (5-8).
1.1.2 Dendritic cell precursors
Human DC are all bone marrow-derived leukocytes. They are distinct from follicular 
DC (FDC), which are not leukocytes but are of stromal origin. (9). DC can originate 
from either common lymphocyte (CLP) or common myeloid progenitors (CMP) 
suggesting a redundancy in their developmental pathways (10) (Figure 1.1). These 
progenitors have been isolated from the bone marrow using a panel of markers. Both 
progenitors share a lack of the "lineage" markers of differentiated haematopoietic cells, 
but express IL-7 receptor in the case of lymphoid progenitors and c-kit in the case of 
myeloid progenitors. However the dual origin of DC is still controversial.
17
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Figure 1.1 DC Development, Diversification, Maturation, and Function.
CD34+ haematopoietic stem cells differentiate into common myeloid progenitor cells 
(CMP) and common lymphoid progenitor cells (CLP). The CMPs differentiate into 
CD34+CLA+ and CD34+CLA~ late progenitor cells that differentiate in blood into 
CD1 lc CDla^ Langerhans cell precursors and CD1 lc +C D la” interstitial DC precursors, 
respectively. These cells migrate into the skin or other tissues in an antigen independent 
way and may undergo a steady-state migration into the draining lymph nodes playing a 
critical role in immune tolerance. CMP and CLP also give rise to myeloid pre-DC 1 and 
lymphoid pre-DC2 in bone marrow. They migrate into the blood and then to the 
lymphoid tissues. During bacterial infection, pre-D Cls ingest and kill bacteria and then 
differentiate into DC and initiate adaptive antibacterial immune responses. During viral 
infection, pre-DC2s rapidly produce large amounts o f type-1 IFN and then differentiate 
into DC and initiate adaptive antiviral immune responses. Blue background is used for 
resting or tolerogenic cells, while yellow background is used for activated cells (figure 
courtesy o f Silvano Sozzani, Universita di Brescia, Italy).
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1.1.3 Dendritic cell subsets
A large variety of DC subsets have been described in lymphoid and non-lymphoid
organs. DC are mainly subdivided into myeloid-related DC (M-DC) and plasmacytoid
DC (P-DC) (11). In the peripheral blood, M-DC precursors express C D llc but lack
CD 123, while the P-DC precursors display the CD1 lc'CD123+ phenotype. Both subsets
are immature, since they are negative for co-stimulation molecules CD80, CD86 and
CD40 (11). Based on in vitro data, there are different pathways for the development of
mature DC from bone marrow CD34+ precursors. Each pathway differs in terms of
progenitors and intermediate stages, cytokine requirements, surface marker expression
and, most importantly, biological function (10). M-DC are distinguished by at least two
distinct pathways of maturation from CD34+ progenitors since, after 5 days in culture
with granulocyte-macrophage colony-stimulating factor, stem cell factor and tumor
necrosis factor (TNF)-a, cells are sorted into either CD14+CDla' or CD14"CDla+
populations (Figure 1.2) (12). In addition, it is likely that under certain conditions
mature monocytes migrate from blood into tissues and differentiate into DC (13).
Substantial diversity exists between M-DC and P-DC, supporting the possibility of
different functional roles. M-DC have several features that allow them to capture
antigens, exploiting a complex array of uptake mechanisms, including phagocytosis,
micropinocytosis and receptor-mediated endocytosis (3), while P-DC have very limited
phagocytic capacity (10, 11). M-DC represent the classic T cell-priming subset, but this
function in P-DC is less clear, although there is definite evidence that P-DC play an
important role in the defense against pathogens and neoplasms (14). Despite the
experimental evidence that circulating and tissue P-DC can acquire the morphological
and functional features of DC in vitro (15), the existence of fully mature P-DC in vivo is
still controversial (14). Furthermore, M-DC and P-DC show marked disparity in tissue
distribution and migration pathways. Immature M-DC are constitutively distributed in
19
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peripheral tissues, especially in the skin and mucosal surfaces, which represent the areas 
of entry of exogenous antigens, where they are responsible for antigen capture and 
processing. Following antigen capture, M-DC undergo maturation into competent APC, 
bearing high levels of MHC and costimulatory molecules (e.g., HLADR, CD80, CD83, 
CD86, DC-LAMP/CD208), and migrate to lymphoid tissues, acquiring potent 
immunostimulatory activity (10), to become mature APC (e.g., interdigitating DC, 
IDC). In contrast to M-DC, P-DC are scarce or totally absent in skin, mucosae and other 
non-lymphoid tissues, while they typically occur in lymph nodes and tonsils, in close 
association with high endothelial venules (HEV) (16). The topographical association 
between P-DC and HEV reflects the migration pathway of this subset of DC, which 
leave the circulation and enter lymphoid tissue through HEV (17). Alternative ways, 
however, exist of migration of M-DC into lymph nodes. Even in the absence of 
inflammation, some DC are found in afferent lymph, suggesting that DC continuously 
traffic from normal tissues to lymph nodes. These rare steady-state migrating DC from 
skin to lymph nodes are phenotypically mature and might be important for immune 
tolerance, eliminating T cells with specificity for self antigens that have escaped the 
thymus during thymic selection (18). Finally, monocytes may undergo differentiation to 
DC upon migration to the lymph nodes (11).
20
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Figure 1.2 Development of human DC subsets.
Precursors in blood and bone marrow (left section) can give rise to four types o f DC 
under cytokine-driven conditions ex vivo. Resident populations o f immature, non 
activated DC (middle section) are normally found in the steady state in the periphery 
and/or the circulation. Semi-mature DC continuously present self-Ags, and probably 
harmless non-self-Ags, in secondary lymphoid organs to maintain peripheral tolerance 
and anergy. Counterparts for these various DC types develop in vitro in the presence of 
the indicated cytokines. Harmful pathogens or other dangerous insults to the steady state 
can lead to inflammation with full maturation and activation o f each DC subset (right 
section). Taken from Rossi, M. et al. 2005 J. Immunol. (19).
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1.1.4 Non lymphoid tissue DC
M-DC include intraepithelial Langerhans cells (LC) and interstitial DC (IN-DC). LC are 
present in the skin and mucosae, they have typical DC morphology and contain 
characteristic Birbeck granules (BG) seen on electron microscopy. Markers are HLA- 
DRY S-100 protein, CDla, E-cadherin and the LC-specific marker langerin (CD207), 
while they lack CD68 and factor XHIa, and most antigens expressed by dermal IN-DC 
(Fig. 1.3). Moreover, LC lack several maturation antigens, such as DCLAMP/CD208, 
while expression of CD83 can be variable (20). In conditions associated with an 
increase or activation of intraepidermal LC, such as contact dermatitis, cells expressing 
a hybrid monocyte-LC phenotype (CDla+C D llb+CD36+CD68+) can be observed (20); 
this observation supports the evidence that LC may derive from monocytes in vivo (13). 
IN-DC are present in the interstitial space of most tissues with the exception of the 
cornea and central nervous system. IN-DC express CD 11c, CD68, factor XHIa, 
macrophage-mannose receptor (CD206), along with the c-type lectin DC-SIGN 
(CD209) (Table 1.1). In analogy with LC, IN-DC lack DC maturation antigens (21) and, 
as with LC, dermal and mucosa IN-DC are strategically localized at the interface with 
the external surfaces where they can take up pathogens (22) and transport them to 
lymph nodes.
The migration of DC from peripheral tissues to lymph nodes is associated with changes 
in their phenotype. LC adhere to keratinocytes via homophilic interactions with E- 
cadherins, and down-regulate this adhesion molecule to leave the epidermis. In the 
lymph vessels and nodal sinuses migrating LC are identified as veiled cells, because of 
their sheet-like lamellipodia; similar to LC, veiled cells express CDla, S-100 protein and 














CD209/DC SIGN - +
E-cadherin + -
Factor XHIa - +
S-100 + -
Table 1.1: Epitopes that distinguish non lymphoid tissue DC
CDla: Type I transmembrane protein related to the major histocompatibility complex 
(MHC) proteins. It forms heterodimers with beta-2-microglobulin and mediates the 
presentation of primarily lipid and glycolipid antigens.
CD llc: Integrin alpha X chain protein that combines with the beta 2 chain to form a 
leukocyte-specific integrin named CR4.
CD68: Transmembrane glycoprotein; member of the lysosomal/endosomal-associated 
membrane glycoprotein (LAMP) family. It binds to tissue- and organ-specific lectins or 
selectins and it is also a member of the scavenger receptor family.
CD206: mannose receptor, C type 1 type I membrane receptor that bind high-mannose 
structures.
CD207: C-type lectin with mannose binding specificity, localized in the Birbeck 
granules, organelles present in the cytoplasm of Langerhans cells.
CD208: member of the lysosome-associated membrane glycoprotein {LAMP) family. 
CD209: C-type lectin receptor acting as both cell-adhesion receptor and pathogen- 
recognition receptor
E-cadherin: Type I transmembrane glycoprotein that mediates calcium dependent cell­
cell adhesion.
Factor XHIa: A subunit of coagulation factor XIII, the last zymogen activated in the 
blood coagulation cascade
S-100: calcium binding protein localized in the cytoplasm and/or nucleus involved in 
the regulation of cell cycle progression and differentiation.
23
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1.1.5 Lymphoid tissue DC
DC have been largely studied in lymph nodes and tonsils (24), where their distribution 
is rather complex, reflecting the occurrence of different subsets of DC, diversity of 
activation and maturation stages and pathways of migration (lymph versus blood 
bome). M-DC-related IDC, represent the majority of mature DC within the lymph node, 
showing bright expression of HLADR and DC-LAMP/CD208 (Fig. 1). IDC are 
predominantly found in paracortical T nodules, where they are intimately admixed with 
T lymphocytes. IDC are considered to descend for the most part from LC, and maintain 
the positivity for S-100 protein (Figure 1.3). However, antigens usually negative on LC 
(such as CD1 lc) are expressed by IDC, while langerin and CDla are generally lost (24). 
P-DC are typically found in the 'traffic area' of lymph nodes and are better identified 
with the help of immunostains that show strong reactivity for CD68, CLA HECA-452, 
CD123, BDCA2 and TCL-1 (25).
Cortical B follicles contain two main DC, the germinal center DC (GCDC) and the 
follicular DC (FDC). GCDC express CD4, CD 13 and CD llc, are strong APC for T 
cells, and can directly regulate B cell responses, producing IL-12 and inducing germinal 
center B cell expansion, plasma cell differentiation, and IL-10-independent isotype 
switching toward IgGl. The origin of GCDC is poorly studied; they might be related to 
the subset of dermal DC that express CXCR5 and traffic to B cell zones in lymph nodes 
(26). FDC do not represent bona fide DC, since they are non-hematopoietic in origin, 
but mesenchymal. In addition, they are not capable of activating naive T cells, do not 
display a capacity for antigen capture and presentation, but do express preformed 
antigen-antibody complexes (antigen carrying cells) on their surface. FDC are typically 
located within primary and secondary B follicles, and interactions between CXC ligand 
13 (B lymphocyte chemoattractant; CXCL13) expressed on FDC and CXCR5 expressed
24
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by B cells and activated T cells play a role in B follicle development and organization. 
FDC express complement and Fc receptors, as well as a series of antigens that are 
useful for revealing them on sections, such as CD21, CD23, CD35, CNA.42, KiM4p, 
DRC1, nerve growth factor receptor, and clusterin (Figure 1.3). The functional role of 
FDC is still controversial (9). The close association with germinal center B cells has 
fostered the idea that B cell recognition of retained antigen on the surface of FDC is 
important for affinity maturation and memory B cell development. However, it is 
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Figure 1.3 Distribution and phenotype of DC subsets in peripheral tissues (skin) 
and lymph node.
In the skin LC are typically confined to the epidermis (A, Al), while IN-DC, here 
stained for macrophage mannose receptor, are found in the dermis (B, Bl). In C and D, 
a drawing and the corresponding picture of a reactive lymph node is shown (cap: 
capsule; Bfol: B follicle; T-nod: paracortical T nodule; Ta: traffic area). Sinus vessels 
are illustrated with dashed lines, HEV as full lines; nodal DC are shown as star-shaped 
cells and include immature DC (red), mature DC (blue), and GCDC (yellow); P-DC are 
shown as round cells (yellow). In the marginal sinus some S-100 protein+ veiled cells 
are present (El; F shows staining for DC-SIGN, which identifies macrophages within 
the marginal sinus (sin), as well as the sinus lining cells and numerous DC along the 
traffic area (Ta); in the inset a double immunofluorescence for DC-SIGN and DCLAMP 
shows that the DC-SICN cells (green) do not express DCLAMP (red). In G, the traffic 
area at the periphery of B follicles and T nodules is clearly depicted by HECA-452 
antibody, which stains P-DC and HEV; in the inset a double immunofluorescence for 
CD 123 and DCLAMP shows that the CD 123+ P-DC (red) do not express DCLAMP 
(green). The paracortical T nodule shown in H contains large numbers of DCLAMP' 
mature IDC (blue), that form close contacts with surrounding T cells (HI); CD 123 in red 
(H) stains the HEV and scattered P-DC mainly localized at the periphery of the T 
nodule. In a secondary B follicle, CD11 c stains GCDC (I), (figure courtesy of Silvano 
Sozzani, University of Brescia, Italy).
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1.1.6 Further distinctions in nomenclature
M-DC and P-DC have been, respectively, labeled DC1 and DC2 because of their 
propensity to stimulate Thl- vs Th2-type responses. This oversimplification, however, 
neglects stimulation of more varied T cell responses. The name DC1 does not take in 
account the function of LC or IN-DC as conventional DC. Skewing toward Th2 
responses by plasmacytoid DC in the presence of IL-3 led to their being termed DC2. 
This has no bearing, however, on their role as tolerogenic DC in inducing CD4+ and 
CD8+ regulatory T cells (27). It also overlooks the major physiologic role of 
plasmacytoid DC as the most abundant source of type I IFNs after activation by viruses 
(15, 28). IN-DC and M-DC have been considered homologous, because both develop 
from a CD14+ precursor. More recent phenotypic and functional data, however, indicate 
that these two types of DC are distinct (29). The specific descriptive term for each type 
of DC is therefore more useful than nomenclature like DC1 vs DC2, or myeloid vs 
lymphoid DC
1.1.7 Dendritic cell maturation
The process of DC maturation is now accepted as a crucial component of the induction 
of adaptive immune responses (Figure 1.4) . The term maturation refers to the 
differentiation process whereby DC respond rapidly to an environmental stimulus and 
become capable of eliciting adaptive immunity. The type of stimulus determines the 
program of DC differentiation and the subsequent immune response. DC can directly 
sense pathogens via TLRs, and respond to this recognition by up-regulating surface 
costimulatory molecules, secreting cytokines and chemokines, enhancing antigen 
presentation, and migrating to secondary lymphoid tissues (30). Some features of DC 
maturation, such as the up-regulation of CD86, can also be induced by proinflammatory 
cytokines, but cytokines alone seem insufficient for the activation of adaptive immunity
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in vivo (31). Additional changes can be imparted to DC by CD40 ligation, which 
contributes to the generation of both CD4 and CD8 T cell immunity (32). So, the DC 
maturation process may be seen as the sensor that links innate immune responses to 
adaptive ones. During TLR-mediated DC maturation, distinct TLR ligands evoke 
distinct responses (30). This signaling complexity is further increased by the expression 
of a distinct TLRs profile by DC subsets, as well as by the differences in adaptor 
molecules used by single TLRs.
1.1.8 DC functions
1.1.8.1 Dendritic cells in T cell activation
DC express a variety of co-stimulatory molecules and produce several cytokines and 
chemokines which contribute to shape the quality of the T cell response. T cells 
establish contact with APCs by forming an immunological synapse, where TCRs and 
CD28 molecules are segregated together in a central area surrounded by a ring of 
adhesion molecules (33). In naive T cells TCRs are inefficiently coupled to signal 
transduction pathways. Engagement of CD28 by B7 molecules expressed on APCs 
recruits membrane rafts containing kinases and adaptor proteins to the synapse and 
amplifies the signalling process initiated by the TCR. Sustained signalling is essential 
for naive T cells to up-regulate anti-apoptotic cytokines, receptors for homeostatic 
cytokines, such as IL-7 and IL-15, and to induce T cell proliferation.(34). A short TCR 
signal leads to abortive T cell proliferation. In contrast a shorter TCR stimulation, even 
in the absence of CD28 mediated co-stimulation, is sufficient for effector T cells to 
induce their proliferation and activate their effector function (35). The balance between 
stimulatory and inhibitory signals in T cell activation is required for effective immune 
response to pathogens and for maintaining self tolerance (Figure 1.4).
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Although the basic principles of DC physiology have been elucidated in considerable 
details, it is difficult at present to draw a general picture on how antigen presentation is 
carried out. A first variable to be considered in T cell priming is the relative contribution 
to antigen presentation of migrating versus resident DC. Indeed some antigens may 
reach the lymph node directly while others need to be ferried by migrating DC. This 
will impact on the frequency and activation state of the antigen presenting DC and 
ultimately on the strength of stimulation that will be delivered to the nai've T cell. Self 
antigens in pancreas, constitutively transported by migrating DC and presented in the 
draining lymph nodes, induce abortive proliferation and establishment of tolerance. In 
the presence of an infectious agent the same antigen delivered to the lymph nodes by 
high numbers of DC expressing co-stimulatory molecules and primed for IL-12 
production induced productive T cell activation and differentiation to effector cells. A 
second variable is the nature of the activating signals received by DC. For instance 
CD40L expression by specific helper T cells can deliver to DC a licensing signal for 
effective CTL priming. DC that have been directly activated by microbial products have 
superior T-cell stimulatory capacity as compared to those that have been activated in a 
bystander fashion by inflammatory cytokines. The third variable is the kinetic of the DC 
activation. Migrating DC that secrete Thl polarizing cytokines will be capable of 
driving Thl differentiation, while the same DC at later time points, having exhausted 
IL-12 producing capacity, will prime T cells that either develop towards Th2 or remain 
non-polarized. The differentiation of nai've CD4+ T cells towards IFN-y producing Thl 
is promoted by IL-12 whereas differentiation towards IL-17 producing inflammatory T 
cells is promoted by IL-23. Mature DC that migrate to the lymph node induce rapid 
recruitment of NK cells and the IFN-y produced by them is necessary for efficient Thl 
polarization in vivo (36). Th2 polarisation is primarily driven by IL-4, but the source of 
this cytokine during T cell priming remains to be determined. Several studies indicated
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that DC under appropriate stimulatory conditions can effectively prime Th2 responses in 
spite of not being able to make IL-4. DC with Th2 polarizing capacity can be generated 
either by maturation stimuli that do not induce IL-12 production or by exhausted DC. 
Since naive T cells upon prolonged stimulation can produce low amounts of IL-4 that is 
sufficient to promote their own differentiation towards Th2, it is possible that Th2 
differentiation would simply result from a lack of Thl polarizing cytokines (37, 38). 
Plasmacytoid dendritic cells are capable of presenting endogenous antigens to CD8+ T 
cells, although their major function is the production of high amounts of type I 
interferons, following viral infection or TLR7 or TLR9 triggering by specific agonists 
(39). Mouse pDC, cultured from bone marrow precursors or isolated from spleen, can 
induce the development of both Thl and Th2 effector cells depending on the dose of 
antigen (39). Thus, as observed for conventional DC, antigen dose, nature of maturation 
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> / :>  /> "  a a




Figure 1.4 Inflammatory signals cause DC maturation but do not license DC to 
drive CD4 T cell effector functions.
Immature DC (top) expressing few MHC class II molecules and the T cell costimulatory 
molecules CD40, CD80 and CD86 are thought to induce tolerance. After recognition of 
pathogen products via TLR ligands (right) or inflammatory signals released by other 
cells (left), they become mature licensed DC or mature unlicensed DC, respectively. 
Both forms of mature DC express abundant MHC class II and costimulatory molecules, 
which enables them to induce the proliferation of naive CD4 T cells. However, only the 
licensed DC can provide an additional signal that drives CD4+ T cell differentiation into 
effector helper cells (bottom right).(Heath, W.R., and al. 2005. Nat Immunol (40))
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1.1.8.2 Dendritic cell role in the induction and maintenance of tolerance
Dendritic cells also play a fundamental role in the induction and maintenance of central 
and peripheral tolerance. Central tolerance in the thymus is achieved by inducing 
apoptotic cell death in potentially self-reactive T cell clones (41). Thymic medullary 
epithelial cells express MHC class I molecules and delete self reactive T cell clones 
with high affinity. Thymic DC represent a particular subset with a different life history, 
because most of them derive from an intra-thymic precursor, develop and die within the 
thymus. Several in vitro and in vivo experiments have demonstrated the ability of 
thymic DC to induce central tolerance. In contrast to their function in negative selection 
thymic DC are neither active, nor required for positive selection, which can be fully 
supported by cortical epithelial cells. The completely different outcome of the DC T cell 
interaction, which in the thymus induces apoptosis instead of T cell activation and 
proliferation, seems to be more related to the T cell differentiation stage rather than 
being a special feature of this DC subset. Central tolerance is efficient, but incomplete: 
self reactive T cells with lower affinity for self antigens, can escape negative selection
(42). However, self-reactive T cell clones are not exclusively deleted by central 
tolerance mechanisms. Tolerance in vivo is achieved also by an active process of 
peripheral control of potentially self reactive T cells. Peripheral tolerance is important 
not only for self antigens but also for other peptides, like harmless environmental 
antigens. It is essential to acquire tolerance in order to avoid a chronic response. Most 
data show that DC are able to induce tolerance at an immature stage (43). Immature DC 
(iDC) can induce tolerance by killing T cells, by inducing T cell anergy, or by 
generating regulatory T cells. In this view continuous steady state DC migration from 
peripheral tissue to lymph-nodes in the absence of any microbial products might 
maintain peripheral tolerance. Indeed, several reports have also shown that low doses of 
soluble antigen induce peripheral tolerance when targeted to DC in steady state; T cell
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proliferation takes place but reactive T cells are subsequently deleted after few days
(43).
In addition to T cell deletion, DC can induce regulatory T cells. At least two different 
regulatory T cell subsets have been identified: naturally occurring regulatory T cells, 
which arise in the thymus and are characterized by the expression of CD4 CD25 and 
FoxP3, and T cells with suppressor function, which are induced in the periphery. This 
last subset of regulatory T cells is CD25 and FoxP3 negative. Both produce 
immunesuppressive cytokines, like IL10 and TGFp and require cell contact for their 
regulatory function (43).
The presence of a danger signal, such bacterial products, inflammatory cytokines, lipid 
mediators and/or NAD+, released by necrotic cells, seems the major strength which 
drives DC to a fully mature phenotype with the ability to activate and induce the T cell 
proliferation and proper immune response. But many questions regarding the 
achievement of peripheral tolerance remain unsolved; when self antigens as well as 
microbial or viral products are present at the same time in the same environment. In this 
regard Medzhitov and Blander recently suggested that compartmentalization and 
presentation of Toll like receptor mediating antigen uptake differs from that mediating 
uptake of phagocytosed apoptotic cells (44). In this regard, even if still under debate, 
necrotic cells might also represent a danger signal, which differs from apoptotic cells. 
Another complex situation in terms of immune regulation is represented by the delicate 
equilibrium of tolerance and immunity against commensal bacterial. In the gut bacterial 
and bacterial products are physically separated from DC by the epithelial layers, which 
might influence the triggering of TLR. Only TLR expressed at the surface of DC might 
be able to sense the environment, whereas intracellular TLRs, like TLR9, 3 and 7, could 
not be engaged by TLR agonists. During an infection, bacteria are in direct contact with 
APCs, and this difference could determine the different outcome of the immune
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response. Tumor transformation also represents a particular situation in terms of 
immune reaction. Neoplastic events might happen continuously throughout the life of 
an individual, but the role of immune surveillance is still not clear, since the incidence 
of transforming events in immune-deficient mice is very low, probably because the 
majority of mutations might induce apoptosis of the cell. Many open questions remain 
to be solved in order to understand the fine equilibrium between tolerance and 
immunity.
1.1.9 Clinical applications of human DC for active immunotherapy
There is great interest in altering the cytokine milieu that drives DC immunogenicity 
(45) or in using DC to expand Tregs for the control of autoimmunity (46). Most current 
clinical studies, however, use DC for active immunotherapy trials in cancer. Most tumor 
Ags are poor immunogens because they are self-Ags or self-differentiation Ags, to 
which there is considerable tolerance. DC provide a potential solution to this challenge 
by coupling tumor Ag with all of the requisite costimulatory ligands, cytokines, and 
chemokine-directed migration to secondary lymphoid organs. There they can stimulate 
incoming T cells to exit via efferent lymph into the periphery as cytolytic and helper T 
cell effectors.
Challenges to designing the optimal DC vaccine include the choice of DC subset or 
combination of subsets. For example, whether the functional distinctions between 
conventional DC subsets in vitro (29) have physiologic relevance in vivo is the subject 
of an ongoing vaccine trial in melanoma. The presumptive advantage of LCs has been 
the rationale for other investigators to include CD34+ HPC-derived DC, which comprise 
LCs among the progeny, in vaccine preparations (47). The malleability of moDC 
precursors under certain cytokine conditions might also yield moDC progeny that 
function more like LCs (48). Other unknowns include optimal Ag-loading strategies
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like peptide pulsing, overlapping polypeptide pulsing, cross-presentation of dying tumor 
cells, fused tumor-DC heterokaryons, DNA or RNA transfection with or without a 
vector construct, frequency and route of immunization, and cell dose. Finally for 
effective vaccination activated and terminally mature DC are needed to avoid any 
reversion to immature DC that may be inactive or even generate suppressive Tregs (49). 
The first human DC vaccine trial used the rare circulating DC isolated ex vivo from 
steady-state pheresis products and loaded with tumor-specific idiotypes to treat patients 
with follicular lymphoma (50). This approach is not selective for any one of several DC 
subsets in blood, and the yields are low. The advent of the cytokine-generated DC era 
has supported large-scale clinical evaluations, and a number of trials were performed. In 
the aggregate, these studies have shown that DC vaccinations are safe and that tumor- 
specific T cell responses can be generated by DC vaccination using standard 
immunologic assays in vitro. Although patients eligible for these early phase clinical 
trials have advanced disease, clinical responses have been achieved in some instances 
(51). Major challenges remain in terms of harnessing the capacity of DC for 
simultaneous presentation of multiple tumor Ags tailored to their own MHC molecules, 
rather than presentation of only a few peptides with defined MHC restrictions. 





The first chemokine discovered was Platelet Factor 4 (now called CXCL4) in the late 
1970s (52), but the existence of a distinct family of small secreted proteins, named 
chemokine because of their leukocyte chemotactic and cytokine-\ike activities, was 
evident only after the cloning of interleukin-8 (CXCL8) in 1987 as an ‘anionic’ 
neutrophil-activating factor and chemoattractant (53). Initially chemokines were 
identified on the basis of their biological activities in culture supernatants and were 
purified biochemically before being sequenced and cloned. More recently, completion 
of the human genome project has led to the final identification in humans of about 50 
structurally and functionally related molecules and it is likely that most of the 
chemokines have now been discovered (54).
1.2.2 Chemokine classification
Chemokines are all small proteins (~8-14 kDa) frequently glycosylated. They bear a
significant sequence identity to each other, and the protein structure is strictly dependent
on 2 conserved disulfide bonds connecting conserved cysteine residues (55, 56).
According to the position and spacing of these cysteine residues, 4 chemokine
subfamilies have been defined: CXC, CC, C and CX3C. The largest group of
chemokines has the first 2 cysteines in an adjacent position (CC chemokines). Most of
these molecules, products of a large multigenic cluster on chromosome 17qll.2, act on
monocytes, whereas other CC chemokines, products of different chromosomal loci, are
active on different cell types (Figure 1.5). In the CXC family, the other large group of
chemokines, the two amino terminal cysteine residues are separated by a single amino
acid. Most of these molecules are coded by 2 large multigenic clusters. The first, located
on chromosome 4ql2-ql3, includes CXC chemokines containing an ELR conserved
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amino acid sequence on the N-terminus (ELR+ CXC chemokines) that act on 
neutrophils. The second, located on 4q21.21, includes CXC chemokines lacking the 
ELR sequence (ELR' CXC chemokines) that act mainly on T lymphocytes (Figure 1.5). 
The third chemokine subfamily includes 2 highly related molecules with only 2 cysteine 
residues (C chemokines), encoded by a single cluster on chromosome lq23, selectively 
active on T lymphocytes. The fourth family (CX3C chemokines) includes a single 
molecule with 3 intervening amino acids between the first 2 cysteine residues. This 
chemokine is coded by a gene located on 16ql3 and acts on monocytes and T 
lymphocytes. It has a transmembrane domain that allows it to be tethered to the cell 
surface like the chemokine CXCL16.
Classically, chemokines have been named according to their expression patterns or 
functions, but due to the rapid discovery of many new chemokines, in 2000 Zlotnik and 
Yoshie (54, 57) proposed a new nomenclature that is based on the type of subfamily 
followed by a progressive number provided by the position of the corresponding coding 
gene in the cluster. Thus, chemokines now are identified by a name providing 
information on the respective structural subfamily, corresponding also to the type of 
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Figure 1.5 The chemokine system: an overview.
Chemokines, their receptors, and predominant receptor repertoires in different leukocyte 
populations are listed. The selected ligands are identified with one old acronym and the 
new nomenclature, in which the first part o f the name identifies the family and L stands 
for “ligand,” followed by a progressive number. Red identifies predominantly 
“inflammatory” or “inducible” chemokines; green, “homeostatic” agonists; yellow 
molecules belong to both realms. Taken from (59)
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NMR spectroscopy and X-ray crystallography studies have provided high-resolution 
structures for a number of chemokines, revealing a conserved fold across subfamilies 
(Figure 1.6), despite low percentage of sequence similarities (60). This common fold is 
composed of a three stranded anti-parallel p-sheet covered on one face by a C-terminal 
a-helix and preceded by a disordered N-terminus (Figure 1.6). Most available structures 
support the formation of chemokine dimers but either absence of dimerization of 
specific chemokines and higher order oligomers have also been reported (61). 
Interestingly, the contact interface is different between the CC and CXC families. 
Dimerization of CC-chemokines involves their N-terminus, in such a way that this 
domain becomes buried in the P-sheet of the other protomer. In contrast, CXC- 
chemokines interact via the pi-strand, leaving the N-terminus accessible. On the basis 
of mutagenesis studies, it was demonstrated that the binding of chemokines to their 
cognate receptors involves the so-called N-loop, which immediately follows the first 
cysteine, and for some chemokines, the N-terminal segment as well. Truncation of the 
unstructured N-terminal domain of chemokines generates in most cases antagonists or 
very partial agonists, illustrating the role played by this domain in the activation of the 
receptor.
Although many studies support the formation of chemokine homodimers, CCL3/CCL4 
and CXCL8/CXCL4 heterodimers have been reported as well (62). Chemokines were 
shown to be secreted by cells as preformed dimers but the dimer dissociation constants 
determined are in the micromolar range, concentrations significantly higher than the 
nanomolar concentrations required for their biological activities in vitro or in vivo. 
However, chemokines are also known to interact with glycosaminoglycans, and this 
interaction was reported to promote the aggregation of chemokines and to increase their
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local concentration at the cell surface (63). Oligomerization might therefore be favored 
in vivo, even at relatively low concentrations. However, numerous studies have reported 
that chemokine mutants unable to form dimers retain their ability to bind and activate 
receptors, arguing that the monomers are the active forms (64). Although synergistic 
effects on cell chemotaxis were reported between Regakine and either CXCL8 or CCL8 
(MCP-3) as well as between CXCL11 (I-TAC) and CXCL12 (SDF-1) (65), this 
phenomenon likely involves post-receptor events rather than chemokine dimerization. It 
is therefore largely accepted that, besides modifying indirectly the actual concentration 
of monomers, dimers do not act as ligands for chemokine receptors, and no solid 
elements exists that would support a link between oligomerization o f ligands and 
oligomerization of receptors.
Figure 1.6 Chemokine subfamilies and chemokine fold
A. Chemokine primary sequences are represented with a black box, disulfide bonds 
connecting conserved cysteine residues are represented by a thin line. CX3C extended 
mucin-like stalk, transmembrane domain and intracellular domain are represented with 
gray boxes. B. The common chemokine fold is composed o f a three stranded anti­





1.3.1 Nomenclature and classification
Chemokine receptors are defined by their ability to signal on binding one or more 
members of the chemokine superfamily of chemotactic cytokines (66). They define a 
distinct subfamily in the class A of the rhodopsin-like G protein-coupled receptor 
family (67, 68). At present, 18 receptors have been defined molecularly, 10 for CC 
chemokines (CCR1 to 10), 6 for CXC chemokines (CXCR1 to 6), and 1 for C 
chemokines and CX3C chemokines (XCR1 and CX3CR1, respectively). In most cases, 
each individual receptor binds multiple chemokines, but subclass restriction is strictly 
respected. Thus, a major functional correlate of chemokine subclassification is 
represented by the use of different receptors whose names include the chemokine 
subclass specificity followed by a number (Figure 1.5).
1.3.2 Tridimensional structure and activation mechanisms
The sequences of chemokine receptors have 25 to 80% aa identity, indicating a common 
ancestor. However, many other G protein-coupled peptide receptors also have ~25% aa 
identity to chemokine receptors, illustrating that the structural boundary is not sharp. 
Although they lack a single structural signature, there are several features that together 
are found more frequently among chemokine receptors than other types of GPCRs. 
These include a length of 340 to 370 aa; an acidic N-terminal segment; the sequence 
DRYLAIVHA, or a variation of it, in the second intracellular loop; a short basic third 
intracellular loop; and a cysteine in each of the four extracellular domains (68).
The three-dimensional structure of chemokine receptors is unknown, but a reasonable 
working model can be constructed for the transmembrane domains based on analogy 
with rhodopsin. Evidence has been reported that CCR2, CCR5, and CXCR4 form
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homodimers, and in the case of CCR2, a dimer has been implicated as the functional 
form of the receptor, which may be needed for signaling (69).
As other GPCRs, chemokine receptors are integral membrane proteins that contain 
seven transmembrane a-helices (TM) linked by intracellular (ICL) and extracellular 
loops (ECL), an extracellular N-terminal domain and a cytosolic C-terminus (70). Most 
class A receptors share two conserved cysteines involved in the formation of a disulfide 
bond between ECL1 and ECL2. As mentioned before, chemokine receptors contain two 
additional conserved cysteines believed to form a second disulfide bond between the N- 
terminus and ECL3. These two disulfide bonds appear as necessary for the proper 
folding of chemokine receptors, the binding of their ligands and/or their ability to 
activate intracellular cascades even if cysteine mutants of CCR5, while strongly 
impaired in terms of chemokine binding, still support HIV infection (71).
Both the N-terminus and extracellular loops of chemokine receptors play a critical role 
in their interaction with chemokines. From mutagenesis experiments, the second 
extracellular loop (ECL-2) of CCR2, CCR5 and other receptors was reported to play an 
important role in the specificity of interaction with CC-chemokines (71, 72). 
Monoclonal antibodies that target this loop are also known to inhibit ligand binding 
(72). A number of acidic amino-acids and sulfated tyrosines located in the N-terminal 
domain of receptors also contribute to the high affinity binding of chemokines (73). All 
available studies converge to a model in which the core domain of the chemokine binds 
to the N-terminus and extracellular loops of the receptor, while the chemokine N- 
terminus interacts with the helix bundle and is involved in receptor activation. The 
proposed model for the binding of a chemokine to its receptor is a two-step mechanism 
(Figure 1.7), in which a first binding interaction of the chemokine with the receptor N- 
terminus allows a second interaction to take place with the extracellular loops and 




Figure 1.7 Model of chemokine receptor-ligand interaction.
A. Receptor is in an inactive conformation. B. Ligand binds to the N-terminus of the 
receptor, leading to a conformational change. C. The conformational change allows for 
ligand binding to the activation domain of the receptor.
During the past few years, our understanding of the activation mechanisms of GPCRs 
has greatly progressed, in part as a consequence of the availability of the 3D structure of 
bovine rhodopsin in its inactive state (75). Biochemical and biophysical approaches, 
supported by modeling studies, have allowed us to identify key structural motifs 
involved in the activation mechanism of GPCRs. Such motifs include the E/DRY box at 
the cytosolic border of TM3 (76) and the NPxxY motif in TM7, which are both highly 
conserved among class A receptors. It is believed that agonists induce relative 
movements of TM3 and TM6 of the GPCR activation by agonists, resulting in the 
opening of a binding pocket for the heterotrimeric G protein. Activation mechanisms 
require the disruption of intramolecular interactions that stabilize the inactive 
conformation of the receptor (77). It is now widely accepted that disruption of these 
constrains is induced by the binding of agonists, and that mutations affecting some of 
the key residues involved in these interactions can lead to the constitutive activity of 
receptors. Naturally occurring mutations leading to increased constitutivity of specific
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receptors have been associated with pathological states (78). One of the best known 
constrains that maintains class A GPCRs in their inactive conformation is the so-called 
“ionic lock” that involves residue Arg in the E/DRY motif of TM3, the adjacent 
Asp/Glu residue, and a partly conserved Asp/Glu residue at the cytoplasmic end of TM6 
(79). The substitution of the charge in one of these Asp/Glu results in an increase of the 
constitutive activity of rhodopsin, adrenergic and hormone receptors
1.3.3 Chemokine receptor signalling
Conventional (i.e. signalling) chemokine receptors, like all other members of the GPCR 
family, mainly transduce intracellular signals through the activation of heterotrimeric G 
proteins, and all chemokine receptors in particular mediate signalling through pertussis 
toxin-sensitive Gcq proteins (80). A common response of all chemokine receptors is, 
almost by definition, the stimulation of cell migration. Stimulation of chemotaxis by a 
chemokine requires the functional coupling of the receptor to Gaj because migration is 
completely inhibited by treatment of the cells with pertussis toxin. However, Gai itself 
appears not to be necessary for cell migration. The essential step is the release of the 
heterotrimeric G protein (3y subunits from Got; and the Gi protein-coupled receptor (81). 
The release of (3y subunits is required, but not sufficient, to induce chemotaxis because 
in addition to G protein-activation, seven-transmembrane-domain receptors generate 
accompanying signals that induce functional responses.
Stimulation of chemokine receptors rapidly activates phosphoinositide-specific 
phospholipase Cp2 (PLC-P2) and PLC-p3 isoenzymes, which leads to inositol-1,4,5- 
trisphosphate (InsPs) formation and a transient rise in the concentration of intracellular 
free calcium ([Ca2+]i). This pathway has been widely used to test the responsiveness of 
chemokine receptors to different chemokines (82). The two PLC isoforms that are
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involved in chemokine-signal transduction become activated by direct interaction with 
py subunits, which are released from the Gapy-receptor complex (83). However in 
neutrophils of mice that lack the genes encoding both isoforms chemokine-induced 
calcium elevation is suppressed, but do not show any defects in chemokine-stimulated 
migration (84), suggesting that calcium influx is not necessary for chemotactic 
response. Chemokine-mediated activation of PLC not only results in InsP3 production 
but also leads to the formation of diacylglycerol and subsequent activation of protein 
kinase C (PKC).
Another well established effector of py subunits is the type Ib phosphatidylinositol 3 
kinase y (PI3Ky) (85). Through this enzyme chemokines stimulate the rapid formation 
of phosphatidylinositol 3,4,5-trisphosphate PtdIns(3,4,5)P3, which is subsequently 
dephosphorylated to become Ptdlns (3,4)P2. Mice that do not express PI3Ky have 
severely impaired chemokine-stimulated signal transduction (85), which suggests that 
PI3Ky is involved in distinct pathways downstream of G protein-coupled receptors. 
Among the best characterized downstream effectors of the PI3Ks is PKB (86). During 
G protein-coupled receptor-stimulated chemotaxis, PKB is rapidly activated and 
recruited to the membrane of the leading edge of the cell (87)
The involvement of py subunits in the activation of mitogen-activated protein kinases 
(MAPKs) by chemokines is less clear, although activation by chemokines is well 
documented (88). Py subunits of the G protein-coupled receptors activate MAPK 
through a PI3Ky-dependent pathway which, in turn, stimulates a Src-like kinase, 
initiating a "classical" growth factor signal transduction cascade that involves She, 
Grb2, SOS, Ras and Raf (89).
The heterotrimeric G protein a  subunits activate Src family kinases (for example, Fgr, 
Lck or Lyn) (90). Stimulation of Src kinases by Got; not only links chemokine receptors
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to Ras activation by an alternative pathway, via She, Grb2 and SOS, but could also 
explain the activation of FAK and Pyk-2 (91) and of downstream effectors by 
chemokines (Figure 1.8)
A characteristic of most chemokine receptors is the induction of short transient signals 
and the rapid termination of receptor activity by receptor phosphorylation, 
desensitization and internalization. Homologous and heterologous desensitization of 
chemokine receptors is achieved by G protein-coupled receptor kinases (GRKs, mainly 
GRK2) PKA and PKC. Receptor phosphorylation causes the binding of arrestins, 
molecules that were previously shown to interrupt receptor activity and to couple to an 
adaptor protein 2 (AP-2) and clathrin-mediated internalization pathway (92). Receptor 
phosphorylation and internalization is agonist-stimulated but not inhibited by pertussis 
toxin. Phosphorylation of chemokine receptors occurs at multiple sites located at the 









Figure 1.8 Chemokine receptor signaling.
Py subunits activated PLC, PI3Ky and indirectly the FAK-related tyrosine kinase Pyk-2; 
GTP-bound Ga; directly activates Src-like kinases. Through intermediate proteins, the 
kinases stimulate the activation of the cytoskeleton-associated kinases FAK and Pyk-2, 
and, possibly via She, the MAPK cascade. These events include several tyrosine residue 
phosphorylations that direct the recruitment and activation o f proteins that contain SH2 
domains. Such mechanisms endorse the py subunit-independent activation o f type Ia 




1.3.4 Silent or decoy chemokine receptors
1.3.4.1 Introduction
As originally formulated at the end of the 19th century, a receptor is a “receptive 
substance which binds a ligand, usually with high affinity and specificity, and elicits a 
cellular response”. Almost one century later, the first decoy receptor (the IL-1 type II 
receptor) was identified, and defined as “a receptor structurally incapable of transducing 
signal but able to recognize the agonist with high affinity and specificity” (94). The 
biological function of decoy receptors is to compete with signalling receptors for the 
ligand, sequester and target it to degradation. Decoy receptors are now recognized as a 
general strategy to negatively regulate primary inflammatory cytokines. In addition, at 
least the IL-1 decoy RII acts as a dominant negative, sequestering a key component of 
the signalling receptor complex, the IL-1R accessory protein (95). Interestingly, in 
phagocytes the IL-1 decoy RII targets the agonist for endocytosis and degradation, thus 
acting as a scavenger (96).
After the initial observation in the IL-1 system, decoy receptors have been identified for 
a large number of cytokines, in particular inflammatory cytokines (95) characterized by 
different structures and signalling properties, including the IL-1R family (IL-18 binding 
protein), the TNFR family (e.g. osteoprotegerin), the IL-10 family (IL-22 binding 
protein), the IL-4/IL-13R family (IL-13R2). In Drosophila, Argos was recently shown 
to act as a decoy for epithelial growth factor (97). The first evidence that a similar 
strategy could also exist in the chemokine system stemmed from the observation that 
under appropriate environmental conditions inflammatory chemokine receptors can be 
uncoupled from the signalling machinery retaining the ability to bind the ligand and 
targeting it to degradation. Under these conditions chemokine receptors have been
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named “functional” decoy receptors, in that they are structurally identical to signalling 
receptors but act as decoys (98)
Subsequently three proteins that bind subsets of chemokines, but exhibit unusual 
properties compared to typical leukocytic chemokine receptors were identified. These 
are DARC (99), D6 (100) and CCX-CKR (101). Despite exhibiting structural homology 
to other chemokine receptors, and showing high affinity interactions with chemokines, 
these molecules do not couple to the major signaling pathways activated by other 
chemokine receptors upon ligand stimulation, and thus do not mediate cell migration. In 
fact, no alternative signals have been described from these receptors, leading to them 
often being referred to as ‘silent’. Furthermore, they exhibit unusual expression patterns 
and, unlike typical chemokine receptors, are difficult to find on peripheral blood 
leukocytes. Recent data have provided further support that these molecules neutralize or 
transport chemokines.
Beside these three chemokine binding proteins another receptor for chemotactic 
molecules, named C5L2, with similar features was recently characterized. This receptor 
binds with high-affinity C5a and the desarginated forms of both C5a and C3a (C5adR74 
and C3adR77) (102). Moreover the receptor US28, encoded by the human 
cytomegalovirus, displays characteristics of a chemokine decoy receptor (103).
1.3.4.2 D6, a pro-inflammatory CC chemokine decoy receptor
Originally identified as a CCL3 binding molecule expressed in murine hemopoietic 
stem cells (104) and soon after in human cells (105) and (106), the D6 molecule is a 
typical chemokine receptor. The 7 TM domain organization is well conserved, the 
overall sequence identity to conventional chemokine receptors is in the 30-35% range, 
similar to the identity rate observed among chemokine receptors, and the N-terminal 
domain presents several charged residues, most likely involved in ligand recognition as
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for other chemokine receptors. Radioligand binding experiments have demonstrated that 
D6 recognizes an unusual broad spectrum of ligands, being able to interact with most 
agonists of inflammatory CC chemokine receptors from CCR1 through CCR5 (105). 
While the ligand binding profile is unusually broad, receptor expression is fairly 
restricted, being D6 only detectable in placenta and on endothelial cells of lymphatic 
afferent vessels in skin, gut and lung (105, 106) (107).
A significant body of evidence has been gathered demonstrating that neither the human 
nor murine D6 sustain signalling activities typically observed after chemokine receptor 
triggering, such as calcium fluxes and chemotaxis (104, 105, 108) Sequence motifs 
critical for G protein coupling and signalling functions of chemokine receptors like the 
DRYLAR/IV in the second intracellular loop as well as the TXP motif in the second 
TM domain are not conserved in D6. Whether these modifications account for D6 loss 
of signalling function, while retaining high affinity ligand binding is presently 
unknown. D6 does not mediate chemokine transfer through endothelial barriers (108). 
When D6 was expressed on a lymphatic endothelial cell line (108) no evidence for 
facilitated chemokine transfer through the cell monolayer was obtained. Conversely, the 
presence of D6 consistently resulted in the degradation of appropriate ligands. Similar 
results were obtained in different D6 cell transfectants. Analysis of biochemical 
properties of D6 indicated that D6-intemalized chemokines are readily released from 
the receptor during vesicle acidification, allowing subsequent ligand degradation and 
leaving D6 free to recycle to the cell surface. Consistently with this, prevention of 
vesicle acidification by pretreatment with ammonium chloride resulted in reduction of 
ligand degradation and accumulation of the receptor in intracellular compartments. 
Thus, in in vitro settings D6 does not mediate signalling activities or support chemokine 














N u c le u s
Figure 1.9 Model of D6 modulation of inflammatory responses in vivo.
In wild-type mice phorbol ester (PMA) initiates an acute and self limiting inflammation 
that is dependent on the generation o f tumor necrosis factor (TNF). Later, genes 
encoding many p-chemokines are induced and transcribed, forming a chemotactic 
gradient that attracts CD4 and CD8 T lymphocytes (T), eosinophils (E) and mast cells 
(M). In D6-deficient mice, the inflammatory response is intense and prolonged, as the 
chemokine half-life is extended. As a result, the skin pathological lesions resemble 
those observed in the human psoriasis. The D6 decoy is found in lymphatic 
endothelium, where it acts as a ‘conveyor belt’ to ‘mop up’ and deliver the chemokines 
to endosomes. Taken from Gerard, C. 2005. Nat Immunol 6:366-368(109).
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To test the potential role of D6 as a regulator of inflammatory chemokine biology in an 
in vivo settings, D6-null mice have been investigated in two different models of local 
inflammation. By using a model of inflammation induced by phorbol ester skin 
painting, Jamieson et al. recently demonstrated that D6-null mice had an exacerbated 
inflammatory response, initiated by TNF and then sustained by inflammatory 
chemokines, with a prominent inflammatory infiltrate that included T lymphocytes, 
mast cells and polymorphonuclear neutrophils (110). Keratinocyte proliferation and 
neovascularization were also observed, leading to the development of psoriasiform 
lesions. In an independent study, Martinez de la Torre et al. reported that D6 deletion 
resulted in an abnormal inflammatory response in a model of skin inflammation induced 
by subcutaneous injection of complete Freund adjuvant (111). In this latter model, 
inflammatory lesions had a faster apparence and showed a more severe evolution in D6- 
deficient animals, which also developed prominent necrosis and neovascularization. At 
short times (e.g. day 7) inflammation evolved in macroscopic granuloma-like lesions in 
a significant percentage of D 6-/- animals, and only in a minority of wild-type 
littermates. Interestingly, differences were not evident at later time points (e.g. day 21). 
Increased levels of inflammatory CC chemokines were detected locally in both models, 
and pretreatment with chemokine receptors blocking antibodies was able to prevent 
lesion development, demonstrating that, in the absence of D6, the increased 
inflammatory response is caused by an inefficient control of the chemokine system. 
Although the specific role of individual CC chemokines in the recruitment of different 
leukocyte populations have not been defined, both reports described an unbalance 
restricted to inflammatory CC chemokines, consistently with D6 binding profile. 
Interestingly, some features were common at both experimental conditions, including 
the predicted derangement of CC chemokines and the unexpected effect on 
neovascularization, while others were apparently restricted to the specific experimental
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model used, such as keratinocyte proliferation and the prominent neutrophil infiltrate, 
possibly sustained by a synergistic effect of CC chemokines on CXC chemokines- 
dependent neutrophil recruitment (110). In synthesis, the two experimental models 
highlighted a non-redundant role of D6 in the control of local inflammation in skin, but 
the molecular mechanisms involved in this effect are still ill defined and deserve further 
investigation, as well as the evaluation of the role of D6 in other tissues (Figure 1.9).
1.3.4.3 DARC: chemokine transport and/or neutralization?
The Duffy blood group antigen was first described in 1950. The same protein acts in 
erythrocytes as an entry receptor for some malarial parasites (112). Interestingly, its 
absence, caused by promoter mutation in Duffy negative individuals, provides 
erythrocyte resistance to malarial infection. It later transpired that Duffy antigen is a 
receptor for various pro-inflammatory chemokines of both CC and CXC subclasses 
(113, 114), leading to its renaming as Duffy antigen receptor for chemokines (DARC). 
Although being the broadest known chemokine receptor, being able to bind 16 
inflammatory chemokines of the CC and CXC families, overall DARC expresses a 
fairly low homology rate with conventional chemokine receptors. Along with 
erythrocytes, DARC is also expressed on vascular ECs, where it is up-regulated during 
inflammation (115). It is particularly prominent at sites of leukocyte extravasation, 
including the high endothelial venules of lymph nodes (116). Importantly, DARC lacks 
canonical intracellular signaling motifs, and does not support any detectable ligand- 
induced signalling or migration. These features have lead to hypotheses that DARC is 
involved in the transcytosis, or neutralization, of chemokines at EC barriers and, on 
erythrocytes, that it may act to regulate plasma chemokine concentrations (99) (Figure 
1.10). Immunoelectron microscopy studies in skin have demonstrated that chemokines 
can be internalized by ECs, transported across the cell, and presented on the tips of
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luminal microvilli, presumably associated with GAGs moreover in vitro data have 
shown that CXCL8 can be transported across an EC monolayer in a DARC-dependent 
fashion (117).
Analysis of inflammatory reactions in DARC-deficient animals has lead to contrasting 
results (118, 119), possibly because DARC might exert a dual function, acting as 
mechanism that facilitates transfer of chemokines across vascular endothelium (120) 
and as a chemokine buffering system (113) (118, 121) under different circumstances. 
Additional evidence for a decoy function of DARC has emerged from studies on mice 
engineered to over-express DARC in ECs. These mice show reduced angiogenic 
responses to certain CXC chemokines. Here, DARC may sequester these chemokines, 
preventing their binding to EC CXCR2, thus blocking angiogenic signals from this 
receptor (122). It has been proposed that DARC expressed by erythrocytes may function 
as a chemokine reservoir, maintaining plasma concentrations of certain chemokines. 
DARC negative humans display reduced plasma levels of CCL2 compared to DARC 
positive individuals and injected chemokines more rapidly disappear from the 
circulation in DARC null mice (99). Thus, erythrocyte DARC may act as a chemokine 
buffer, sequestering chemokines present at high levels in the serum, but maintaining a 
homeostatic level as their presence subsides. Because plasma chemokines desensitize 
circulating leukocytes, careful buffering by DARC may control leukocyte sensitivity to 
pro-inflammatory chemokines, limiting under- or over responsiveness.
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Figure 1.10 Contribution of EC and erythrocyte DARC to chemokine function.
Chemokines (depicted as hieroglyphs in black) are produced in the extravascular 
compartment by the tissue cells and are not “seen” by leukocytes in circulation. EC 
DARC transports chemokines in abluminal to luminal direction and are immobilized by 
the GAGs (a). These GAG-bound chemokines (green) can activate leukocyte integrins 
and convert leukocyte rolling into firm adhesion. Alternatively, chemokines may diffuse 
through the EC junction (b) bypassing the GAGs leading to free soluble chemokines in 
plasma (red) that trigger cognate receptors on blood leukocytes (c) resulting in 
leukocyte “desensitization”. The free plasma chemokines (black) might bind to DARC 
on erythrocyte (RBC) surface (e) and cannot induce neither leukocyte adhesion nor 
desensitization. Thus, the same chemokine molecule (black, red or green) may play 
dramatically different functional roles in the process o f leukocyte— EC adhesion and 
emigration and the interactions with DARC determine the microanatomical position o f 
chemokines and through it their function. If not bound to the erythrocyte DARC, 
chemokines disappear from plasma into the lungs and kidneys (d) with yet unknown 
functional outcome.Taken from Rot, A. 2005 Cytokine Growth Factor Rev (99).
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1.3.4.4 CCX-CKR, a decoy receptor for constitutive chemokines?
CCX-CKR binds the constitutive CC chemokines CCLs 19, 21, and 25 and also weakly 
to the follicular CXC chemokine, CXCL13, at least in humans (123). Similar to D6 and 
DARC, ligand-induced signals cannot be detected in response to ligand stimulation, and 
this receptor is therefore unlikely to mediate chemotaxis (101). There is little known 
regarding the biochemistry, expression, and function of CCX-CKR at present, but its 
ligand binding profile provides a compelling case for its involvement in developmental 
or homeostatic lymphocyte trafficking, or during the generation of immune responses. 
PCR and Northern blot analysis of mouse tissues show CCX-CKR to be widely 
expressed. It is expressed on T lymphocytes and immature dendritic cells, it binds 
selectively homeostatic CC chemokines and might represent the functional counterpart 
of D6 which selectively binds inflammatory CC chemokines. In this respect, the 
expression of CCX CKR in lymph nodes is particularly intriguing. CCX CKR does not 
transduce signalling activity after ligand engagement, and intriguingly also in this 
receptor the DRY motif in the second intracellular loop is not conserved. No 
information is available at present on the ligand internalization properties of CCX CKR.
1.3.4.5 The HCMV encoded receptor US28
The 7 TM domain receptor US28, encoded by the human cytomegalovirus, was 
originally recognized as a receptor for a large panel of CC inflammatory chemokines 
(124) and and more recently also for CX3CL1 (125). US28 is not a “silent” receptor, it 
is a constitutively signalling receptor (125),(126) that supports ligand scavenging by 
means of constitutive endocytosis and recycling (103). Molecular mechanisms involved 
in US28 cycling are presently unclear. While constitutive agonist-independent 
phosphorylation of serine/threonine residues on the C-terminal domain of the receptor 
have been proven to be required for receptor internalization (127), the role of
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constitutive signalling activity has not been investigated, and the involvement and 
functional role of P-arrestin is presently controversial (128). Whatever the mechanism 
involved, clear evidence that US28 acts as a viral mechanism to blunt inflammation by 
sequestering inflammatory chemokines has been provided (129) , thus making US28 a 
candidate chemokine decoy receptor .
1.3.4.6 C5L2
The fourth “silent” receptor, called C5L2, is highly expressed in neutrophils and binds 
C5a, C5a des-Arg, and possibly other anaphylatoxins (130). As for other “silent” 
receptors, modifications in the DRY motif are responsible for C5L2 being structurally 
unable to couple G proteins and to sustain signalling activity (102). When investigated 
in cell transfectants, C5L2 was unable to undergo ligand-dependent internalization, 
although ligand-dependent receptor phosphorylation was observed, while more recently 
C5L2 internalization after C5a engagement has been reported in neutrophils (131). 
Whether C5L2 is capable of constitutive (i.e. ligand-independent) cycling and what is 
the fate of the ligand after receptor interaction have not been investigated, but in vivo 
results during experimental sepsis correlate C5L2 levels with positive prognosis (131), 
highlighting a possible role of C5L2 in blunting C5a proinflammatory effects. Thus, 
both in vitro and in vivo results candidate C5L2 as a chemoattractant decoy receptor.
1.3.4.7 Other chemokine decoy receptors?
Using these molecules as representatives, a molecular identikit of chemoattractant 
decoy receptors can be attempted (
Table 1.2). First absence of signalling activity that may be due to alterations in the 
DRYLAR/IV motif in the second intracellular loop, which is critical for G protein 
coupling and signalling functions in conventional receptors. A second common property
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of decoy receptors appears to be their ability to act as scavenger receptors and it is 
interesting to note that at least in the case of some chemokine decoy receptors 
constitutive cycling has been demonstrated. It is presently unknown whether 
constitutive cycling is common to all chemokine decoy receptors, but it is tempting to 
hypothesize that this unusual feature may represent a second common property 
identifying this class of molecules. The third characteristic shared by chemoattractant 
decoy receptors is the ability to recognize broad panels of ligands. This task seems to 
have been achieved by shaping the N-terminal extracellular domain, that is the major 
determinant of multispecific chemokine binding both for DARC (132) and US28 (133). 
The prospect that other receptors may also fulfill this role must also be considered. 
These may emerge from the banks of orphan heptahelical receptors currently known, 
and in this prospective it is also noteworthy that the presently orphan chemokine 
receptor HCR also presents alterations in the DRYLAR/IV motif (134), and therefore 
may be considered a further candidate for this family.
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Table 1.2 Structural and functional properties of candidate chemoattractant decoy 
receptors.
The table summarizes the most relevant characteristics of the “silent” chemokine 
receptors D6 and DARC, the CMV-encoded chemokine receptor US28, the orphan 
chemokine receptor HCR, and the “silent” C5a receptor C5L2. In “Structural features” 
the sequence substituting the highly conserved DRYLAIV motif in the second 
intracellular loop is shown.
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1.3.5 Orphan chemokine receptors
1.3.5.1 Introduction
The completion of the human genome sequencing project has identified approximately 
720 genes that belong to the G-protein coupled receptor (GPCR) superfamily. 
Approximately half of these genes are thought to encode sensory receptors. Of the 
remaining 360 receptors, the natural ligand has been identified for approximately 210 
receptors, leaving 150 so-called orphan GPCRs with no known ligand or function. 
Between them there are few receptors that share features found more frequently among 
chemokine receptors than other types of GPCRs (Cytokine Receptor Database: 
http://csp.medic.kumamoto-u.ac.ip/CSP/Receptor.htmr) and for this reason they are 
tentatively classified as orphan chemokine receptors.
Phylogenetic clustering methods were also used to elucidate the chemical nature of 
receptor ligands, which led to the identification of natural ligands for many orphan 
receptors. Interestingly no Drosophila members belong to this group of receptors 
suggesting these receptors might have a recent evolutionary origin (135). Chemokine 
receptors are represented by two clusters (Figure 1.11). The first cluster contain CCR1- 
5, CCR8, CX3CR1, XCR1, D6 and the orphan receptor CCRL2, while the second 
cluster contains CXCR1-6, CCR6, CCR7, CCR9 and CCR10, CCX-CKR, DARC and 
the orphan receptors AMDR, RDC1, CML2 and Q96CH1. This analysis strongly 
suggests that CCRL2 might bind to CC- type chemokines.
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Figure 1.11 Phylogenetic trees of chemokine receptors
Trees were inferred as described in (135). The scale bars indicate a maximum likelihood 
branch length of 0.1 inferred substitutions per site. Silent/decoy receptors are 
underlined, orphan receptors are boxed. Modified from Metpally, R.P.et al. 2005 BMC 
Genomics (135).
1.3.5.2 CCRL2
CCRL2 was first cloned from a human neutrophil cDNA library and named HCR 
(Human Chemokine Receptor) (134). The deduced protein sequence of CCRL2, at 
amino acid level, is most closely related to CCR1 with 43% amino acid homology. 
CCRL2 gene is located at the edge of the main chemokine receptor cluster in the 3p21 
region of the genome composed by XCR1, CCR1, CCR3, CCR2 and CCR5 (136, 137). 
As mentioned above phylogenetic analysis has shown that CCRL2 is a typical member 
of the chemokine receptor family and have given the suggestion that the cognate ligand 
may be a CC chemokine (135). CCRL2 distribution in human leukocytes has been 
recently reported at the mRNA and protein level (138). Migeotte et al., using FACS 
analysis and a monoclonal antibody, found that CCRL2 is expressed by the majority of 
T lymphocytes (CD3*), both on CD4+ and CD8+ cells and that it was present on the vast 
majority of memory T cells, and on about half of naive T cells. CCRL2 is also
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expressed on the majority of natural killer cells (CD56+), but not on B cells. Moreover 
CCRL2 was found on neutrophils, monocytes and monocyte-derived dendritic cells 
with some donor-to-donor variability. CCRL2 expression is enhanced both on T cells 
after stimulation with OKT3 and IL-2 and in dendritic cells following stimulation by 
lipopolysaccharides, poly (I:C), IFN-y or CD40L.
Yoshimura and collegues have recently found that CCRL2 is expressed by all 
infiltrating neutrophils and by some macrophages obtained from the synovial fluid (SF) 
of rheumatoid arthritis (RA) patients. In vitro studies of primary neutrophils revealed 
that CCRL2 mRNA is rapidly up-regulated following stimulation with 
lipopolysaccharide or tumor necrosis factor and that cells expressing CCRL2 migrated 
in response to a fraction of RA SF (139).
CCRL2 murine counterpart, named L-CCR, was originally described to be expressed in 
murine macrophages (140). More recently, L-CCR expression was also demonstrated in 
glial cells stimulated with LPS (141). A single publication reported functional activities 
after L-CCR engagement by CCL2, CCL5, CCL7 and CCL8, in the absence of any 
direct ligand/receptor interaction evidence (142).
1.4 Chemokine/chemokine receptor functions
1.4.1 Role in physiology
Although distinct chemokines exert several biologic functions, including regulation of
hematopoiesis, fibrosis, and angiogenesis, their major (and eponymous) function is
represented by the ability to induce directional cell migration, thus coordinating
leukocyte recruitment in physiologic and pathologic conditions. Leukocyte contact with
endothelium might be transient, reversible, and activation-independent. In this phase,
cells roll across the endothelial surface through chemokine-independent interactions of
selectins with counteradhesins. At inflamed sites, leukocytes enter a second phase
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involving chemokine receptor engagement by chemokines immobilized to 
proteoglycans on the endothelial surface. Chemokine receptor engagement activates P2 
integrins, allowing leukocyte high-affinity binding to endothelial cell counterreceptors 
and subsequent extravasation (143) (Figure 1.12). The simultaneous action o f 
chemokines and integrins is also needed for full activation o f leukocytes and, in synergy 
with primary cytokines, enhances phagocytosis, superoxide production, granule release, 
and bactericidal activity.
Figure 1.12 Chemokine biologic functions.
All chemokines share a common biologic property represented by leukocyte 
chemoattraction and recruitment during immune responses. (1) cell adhesion, (2) 
integrin activation, and (3) cell migration (figure courtesy o f Alberto Mantovani, 
University of Milan, Italy).
Chemokines act as intercellular signals, being produced under appropriate conditions by
virtually every cell type and acting on several target cells, including leukocytes. Some
chemokines are produced constitutively, but most o f them are inducible. In general,
proinflammatory cytokines such as TNF, IL-1, or IFN-a. up-regulate inflammatory
chemokines, whereas anti-inflammatory mediators, such as IL-10 and glucocorticoids,
have an opposite effect. Most inducible chemokines are regulated at the transcriptional
level, but some are stored in platelet granules for immediate release, as in the case o f
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CXCL4 and CCL5. Chemokine receptors also are subjected to expression control. It is 
interesting that receptors for inflammatory chemokines usually are regulated opposite to 
the ligands, and several receptors are detected (or functional) exclusively in specific cell 
states (eg CXCR3 on activated T cells). Although narrow- and broad-spectrum 
chemokines exist, the spectra of action of different proteins usually widely overlap, 
presumably to provide flexibility and specificity in leukocyte trafficking. Neutrophil- 
targeted chemokines are found mainly in the CXC subfamily, whereas 
monocyte/macrophages, eosinophils, and basophils are attracted mainly by CC 
chemokines (Figure 1.13). Both CC and CXC subfamilies also contain T lymphocyte- 
specific members. Specific chemokine receptors mark TH1 (CXCR3 and CCR5) vs 





















Figure 1.13 Role of chemokines in polarized immune responses.
During type I and type II immune responses, master cytokines, represented by 
interferon (IFN)-y and interleukin (IL)-4, respectively, regulate chemokine production 
by stromal and inflammatory cells. Chemokines then support selective recruitment o f 
polarized T cells and specific type I and type II effector cells expressing distinct panels 




1.4.2 Role in disease
Considerable progress has been achieved in our knowledge of the function of the 
chemokine system and in understanding its role in the pathophysiology of human 
diseases. This complex system (approximately 50 cytokines and 20 receptors) 
coordinates leukocyte recruitment in a variety of human diseases, ranging from 
infections and inflammation to cancer. Leukocyte recruitment and activation are key 
steps in the pathogenesis of several human diseases.
1.4.2.1 The Chemokine System in Inflammatory and Infectious Diseases
Since the description of the first chemokine an impressive amount of information has 
been accumulated, correlating the chemokine system with the pathogenesis of 
inflammatory-based disorders (145). A nonredundant role of CXCL8 in neutrophil- 
mediated inflammatory disease has been demonstrated. CXCL8 neutralization results in 
almost complete protection from multiple inflammatory challenges, (146) by genetic 
deletion of CXCR2 that causes defective neutrophil recruitment, (147) and more 
recently by pharmacologic inhibition of CXCR1 (148). Gene-targeted studies also 
demonstrated the importance of CC inflammatory chemokines and respective receptors 
in monocyte recruitment. CCR1'7' and CCR2’7" mice present altered Schistosoma egg or 
purified protein derivative-induced granulomatous inflammation that correlates with 
abnormal TH1 and TH2 cell responses. CCR1"7' mice also have reduced pancreatitis- 
associated pulmonary infiltration, and CCR5'7' mice have enhanced delayed 
hypersensitivity reactions and increased humoral responses to T cell-dependent 
antigenic challenge. Collectively, these results demonstrate a nonredundant role for 
inflammatory chemokines in leukocyte recruitment associated with acute and chronic 
inflammatory responses. Studies with gene-targeted animals also have demonstrated a
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role for chemokines in host defense. For example, CXCR2"7' and CCRT7' mice have 
increased susceptibility to Aspergillus fumigatus inoculation, whereas CCR5'7' and 
CCR2 7" mice are more susceptible to Listeria monocytogenes infection (147). Although 
chemokines and chemokine receptors probably evolved to coordinate leukocyte 
recruitment to support antimicrobial responses, many have been exploited by infectious 
agents to facilitate infection. Two models have been identified. In a first scenario, 
pathogens interfere with the chemokine system by producing chemokine-binding 
molecules, such as the M3 protein secreted by cells infected with murine y herpesvirus 
68 (149), or by pirating chemokines or chemokine receptors and modifying them to 
generate antagonists or chemokine scavengers (150). A second mechanism is 
represented by exploitation of cellular receptors for cell entry. A first example of such a 
mechanism is represented by the malaria-causing protozoan Plasmodium vivax, which 
enters erythrocytes by using a chemokine promiscuous receptor called DARC (112) A 
second example is HIV-1, which gains access to immune cells using CD4 as a primary 
cellular receptor and a chemokine receptor, CXCR4 or CCR5, as strain-specific 
coreceptors. A variety of blocking agents, including agonists, antagonists, and 
antibodies, clearly have demonstrated a nonredundant role for CCR5 and CXCR4 in 
HIV infection. Moreover, a clear-cut role for CCR5 has also been demonstrated through 
the discovery that a mutant allele bearing a 32-base-pair deletion in the open reading 
frame (CCR5-A32), which encodes a truncated and inactive receptor not translocated to 




1.4.2.2 Role of the Chemokine System in Autoimmune Diseases
Leukocyte recruitment, accumulation and activation are common events characterizing 
autoimmune diseases. The use of potent and cytotoxic immunosuppressive therapies for 
the treatment of these diseases reflects limited understanding of the mechanisms that 
allow leukocytes to be recruited to the chronic inflammatory reaction characteristic of 
autoimmune diseases. The importance of chemokines and chemokine receptors in the 
pathogenesis of autoimmunity was initially suggested by many animal models, and 
more recently obtained further support by genetic evidences and clinical studies. In 
animal models of multiple sclerosis (MS), experimental autoimmune encephalomyelitis 
(EAE) and rheumatoid arthritis (RA), chemokines levels correlate with disease 
progression (151, 152), and the treatment of affected mice with chemokine antagonists 
or blocking antibodies has provided the first proof of concept attesting the involvement 
of chemokines in autoimmune diseases (153). More recently, knockout mice have 
revealed that the absence of a chemokine or its receptor may prevent or attenuate the 
insurgence of autoimmune diseases. For example, the absence of CCR1 and CCR2 is 
protective in EAE (153), and CCL3 deficiency in non-obese diabetic mice is protective 
for induced insulitis and spontaneous diabetes (154). Consistently with results obtained 
in animal models, clinical studies have demonstrated that chemokines and chemokine 
receptor expression is significantly altered during the evolution of certain autoimmune 
diseases. In RA patients, clinical disease activity correlates with CCL2 and CCL5 levels 
(155), which have been proposed as clinical markers. Moreover, methotrexate treatment 
of RA patients correlates with a reduction of CCL5 levels (156). Elevated serum levels 
of CXCL10 have been associated with clinical activity of systemic lupus erythematosus 
disease (157). Elevated levels of inflammatory CC chemokines (CCL3, CCL4 and 
CCL5 in particular) and their receptors (CCR2, CCR3 and CCR5) have also been found 
in the central nervous system of MS patients (158, 159), and T cells from MS patients
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treated with IFN-p showed reduced CCR5 expression and inhibition of cell migration to 
its ligands CCL5 and CCL3 (160). A relevant role of CCR5 in T cells recruitment to 
brain lesions correlates with recent genetic evidence showing that MS patients with the 
A32 CCR5 allelic variant, are not protected in the initial phase but have a lower risk of 
recurrent clinical disease (161).
1.4.2.3 Role of Chemokines in Allergic Diseases
Allergic inflammation is a Th2 disease associated with the selective recruitment of 
eosinophils and allergen-specific Th2 lymphocytes. Selective expression of chemokine 
receptors on these leucocytes was postulated to be the mechanism by which they are 
selectively recruited to the allergic site (162-164). In vitro and in vivo studies have 
provided evidence that CCR3, CCR4 and CCR8 are involved in the recruitment of Th2 
lymphocytes (165). Mouse models with blocking antibodies against CCR3 and CCR4 
ligands (CCL11, CCL22 and CCL17) show decreased airway inflammation and airway 
hyperresponsiveness (AHR) (166-168) while neutralization of CCR8 ligand (CCL1) has 
no effect on the recruitment of Th2 cells in the lung (164). However genetically 
modified animals do not confirm in vivo data obtained with inhibitors: CCR3 ‘A mice 
have reduced eosinophil recruitment to the lung after allergen challenge, but increased 
AHR (169), CCR4 "A mice show no protection against development of allergic 
inflammation (170) and two studies out of three reported no effect of CCR8 deficiency 
on the development of allergen-driven airway inflammation (171). The number of 
CCR4+ and CCR8+ T cells in human lung biopsies was increased after allergen 
challenge. Moreover CCL22 and CCL17 levels were increased after allergen challenge, 
while until now CCL1 and CCL11 expression were not detected (172, 173)
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1.4.2.4 Role of Chemokines in Neoplastic Diseases
Chemokines and chemokine receptors have been found expressed in almost all tumors, 
but at now no evidence exists about their involvement in cancer pathogenesis. It is 
likely that chemokines have important effects on cancer pathobiology because they 
affect different activities that impact cancer like leukocyte infiltration, metastatic 
potential, tumor growth and angiogenesis (174-176). The composition of the tumor 
infiltrate is related to tumor and stromal cell production of chemokines. In vitro and in 
vivo experiments suggest that the chemokine CCL2 can suppress tumor growth 
inducing a dense mononuclear infiltrate (177). Moreover it has been demonstrated that 
the same chemokine is able to act as adjuvant to enhance T-cell dependent host anti­
tumor response (178). However most clinical and epidemiological studies suggest that 
chemokine expression might be advantageous for the tumor. In ovarian and breast 
cancer chemokine levels (CCL2 and CCL5) correlate with macrophage infiltration, 
lymph node metastasis and clinical aggressiveness (179-182). In contrast high serum 
levels of CCL2 in pancreatic cancer patients correlate with macrophage infiltration and 
with positive prognosis (183). Chemokines may also help the tumor to subvert the 
immune system by the polarization of the immune response to a Th2 type in order to 
suppress specific anticancer responses. Examples are given by Hodgkin’s lymphoma in 
which there is a prominent production of Th2 chemokines by Reed-Stemberg cells 
(184) and by the human Kaposi sarcoma-associated herpes virus (KSHV) that encodes 
three chemokines (v-MIPI, II and III) that selectively attract Th2 lymphocytes (185). 
Cancer cells not only produce high levels of chemokines but also may express 
functional chemokine receptors. CXCR4 appears to be expressed by the majority of 
cancer cells (23 different types of cancer: for example breast, prostate, pancreatic, lung 
and ovarian carcinomas) (175). CCR7 is expressed by gastric and esophageal carcinoma 
cells and by melanoma (186). Experimental murine cancer models provide some proof
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that cancer cells may use chemokine receptors in order to migrate to metastatic sites 
where their ligands are overexpressed (186). Data from 600 prostate cancer patients 
revealed that CXCR4 protein expression was higher in localized and metastatic prostate 
cancer compared to normal or benign prostatic tissue (187). Chemokines may also act 
as growth and survival factors in an autocrine and/or paracrine manner. For example 
melanoma cells express high levels of CXCR2 and also produce constitutively CXCL1 
and CXCL8 that in an autocrine way stimulate proliferation and survival (188). Prostate 
cancer cells, glioblastoma cells express CXCR4 and CXCL12 stimulate their 
proliferation (187). Furthermore, chemokines may regulate angiogenesis within both 
primary and metastatic tumors. ELR+CXC chemokines promote angiogenesis while 
ELR'CXC chemokines are anti-angiogenic CXCL10 levels in lung cancers are inversely 
related to tumor progression (189), while CXCL5 levels in NSCLC are correlated with 
the vascularity of the tumor and angiogenesis (165).
1.4.2.5 Role of Chemokines in Vascular Diseases
Atherosclerotic plaques are thought to result from an inflammatory response to arterial 
damage (190). Chemokines may be involved in different steps of this inflammatory 
disease: first they can mediate monocyte firm adhesion to vascular endothelium and 
migration to subendothelium where they become the foam cells originating fatty 
streaks. Moreover chemokines may be involved in the later stage of the disease 
activating macrophages and migration of smooth muscle cells into the intima and at the 
end in the thrombus formation over the plaque (191, 192). Animal models of 
atherosclerosis have revealed a role for many chemokines such as CXCL8, CXCL12, 
CXCL10, CCL1 (193-196). Both CCL2‘A and CCR2 mice have 65-85 % less arterial 
lipid deposition than normal mice in hypercholesterolemia models. Disease reduction is 
correlated with decreased macrophage infiltration into the arterial wall, suggesting that
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CCL2 attracts CCR2-bearing monocytes to the vessel wall (197, 198). Moreover proof 
of concept of the role played by CCL2 and CCR2 in this disease derives from the use of 
a CCL2 antagonist that is able to prevent monocyte recruitment in a coronary artery 
remodelling system (199). CX3CR1'7' mice are protected against diet-induced 
atherosclerosis (200, 201). Interestingly it has been reported that a polymorphism 
(V280) in this receptor correlates with protection from coronary artery disease (202, 
203). The relevance of the chemokine system in the human disease is supported by data 
from human lesions: CCL2, CCL5, CCL3, CCL11 and CX3CL1 have been detected 
within atherosclerotic plaques (204, 205). Moreover clinical data reveal that members of 
the statin family inhibit expression of CCL2 (206), suggesting that these drugs may 
reduce atherosclerotic risk by inhibiting macrophage recruitment into the arterial wall.
1.4.3 Role of chemokines in dendritic cell biology
DC are highly mobile and differentially localized to tissues for the regulation of 
immunity. They are positioned as sentinels in the periphery, where they frequently 
encounter foreign antigens, and they readily relocate to secondary lymphoid organs, 
particularly lymph nodes, to position themselves optimally for encounter with naive or 
central memory T cells. The trafficking of DC to lymph nodes through afferent 
lymphatic vessels is crucial for the execution of their functions. Chemokines play a 
fundamental role in DC trafficking (185) even if recent work has documented that many 
chemotactic agonists, different from chemokines, play a relevant role in DC subset 
recruitment (16). Furthermore, chemokine receptor expression is not predictive of DC 
migration since multiple factors, including prostaglandins, leukotrienes, sphingosinel- 
phosphate, extracellular nucleotides and some membrane proteins (e.g. CD38) play an 
important role in the regulation of chemokine receptor function (16). Therefore, DC
73
Chapter 1-Introduction
migration in vivo is a tightly regulated process controlled at the level, of chemokine 
production and chemokine receptor expression and function.
1.4.3.1 Recruitment of myeloid dendritic cells 
Immature DC express a unique repertoire of inflammatory chemokine receptors (e.g. 
CCR1, CCR2, CCR5, CCR6) (207). These receptors bind a pattern of “inflammatory” 
chemokines, including CCL5, CCL2, CCL3, CCL4 and CCL20 (Table 1.3). In addition, 
immature DC also express functional CXCR4 (208), the receptor for CXCL12, 
chemokine that is constitutively expressed in many lymphoid and non-lymphoid tissues.
Receptor Ligand
CCR1 CCL3, CCL5, CCL7
CCR2 CCL2, CCL8, CCL13
CCR4 CCL17, CCL22




CXCR3 CXCL9, CXCL10, CXCL11
CXCR4 CXCL12
Table 1.3 Ligand specificity of chemokine receptors expressed by dendritic cells
Taken from Sozzani, S. 2005.Cytokine Growth Factor Rev (16)
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Little is known about the mechanisms that regulate the homing of DC or their 
precursors, in steady-state conditions (209). CCR2 plays a role in the localization of 
Langerhans cell precursors (210) and transgenic mice over expressing CCL2, under the 
keratin promoter, have local accumulation of cells with DC morphology in the basal 
layer of the epidermis (211). CCR6 and its ligand CCL20 seem to be important for the 
homing of DC to mucosal surfaces but not for the basal recruitment of Langherans cells 
in the skin. In fact CCR6~f~ mice have normal numbers of skin DC cells while they 
have a defect in humoral immune response to oral antigens (212).
1.4.3.2 Migration of DC to lymphoid organs
DC maturation is associated with a dramatic change in their repertoire of chemokine 
receptors. Receptors for inflammatory chemokines are down-regulated while cells start 
to express CCR7 the receptor for CCL19 and CCL21, two homeostatic chemokines, 
highly expressed in secondary lymphoid organs, like tonsils, spleen and lymph nodes 
(213) In vitro exposure of DC to LPS, IL-1, and TNF, or the culture in the presence of 
CD40 ligand, induced a rapid (<1 h) inhibition of chemotactic response to CCL3, 
CCL4, CCL5, CCL7, C5a and formylated peptides (fMLP) (Figure 1.14) (208, 213- 
215). Receptor desensitization by endogenously produced chemokines is likely to be 
responsible for this effect, however, the reported desensitization to C5a and fMLP, two 
chemotactic factors that are not produced by activated DC, implicates additional 
agonist-independent mechanisms (208) (215). Inhibition of chemotaxis is followed, 
with a slower kinetics, by the reduction of membrane receptors and by the down 
regulation of mRNA receptor expression (208, 213). Concomitantly, the expression of 
CCR7 and the migration to CCL19 and CCL21 is strongly up regulated, with a maximal 
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Figure 1.14 Chemokine receptors expressed by dendritic cells.
Immature DC express many chemokine receptors for inflammatory chemokines. 
Inflammatory signals (e.g. LPS, IL-1 and TNF) or immune stimuli (e.g. CD40 ligation) 
induce DC maturation that is associated to the downregulation of inflammatory 
chemokine receptors and the expression of CCR7. CCR7 plays a pivotal function in the 
migration of DC to draining lymph nodes. HCR is the original name of CCRL2 (figure 
courtesy of Silvano Sozzani, University of Brescia, Italy).
The crucial role of CCR7 and its ligands is clearly observed in vivo in mice deficient for 
these proteins. In mice homozygous for an autosomal recessive mutation, paucity of 
lymph node T cells (pit), naive T cells fail to home to secondary lymphoid organs. The 
pit mutation is associated with the lack of expression of one of the two forms of CCL21, 
named CCL21-Ser, present in the secondary lymphoid organs, and in a defect in the 
expression of CCL19 (216). As a consequence of the lack of CCL21 within secondary 
lymphoid organs, DC from these mice fail to accumulate in the spleen and in the T cell 
areas of lymph nodes (Figure 1.15). (217). Similarly, CCR7_/_ mice showed a defective
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architecture of secondary lymphoid organs and a defective homing of DC and 
lymphocytes (218).
CCR7 expression by DC was shown to be required also for the entry of DC into 
lymphatic vessels at peripheral sites both in steady state and inflammatory conditions 
(219). CCR7_/_ mice are characterized by the absence of C D llc+MHCIIhlgh DC, a 
subpopulation of DC that is postulated to migrate in a semimature state of activation, 
from the skin to the draining lymph nodes to maintain tolerance under steady-state 
conditions (219). During inflammation, the entry of DC into lymphatic vessels is 
boosted by the up-regulation of CCL21 on lymphatic endothelial cells. Therefore, 
inflammatory stimuli not only promote the recruitment of immature DC into tissues but 
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Figure 1.15 Expression of CCR7 ligands and fate of dendritic cells in wt and pit 
mice.
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a) The CCR7 ligand CCL19 is expressed by DC after their maturation. In mice, there 
are two known functional genes that encode CCL21. One form o f CCL21, CCL21-Leu 
(purple), is expressed in the periphery, at a minimum by initial lymphatic vessels. The 
other form of CCL21, CCL21-Ser (red), is expressed in lymph nodes, including in the 
terminal lymphatic vessels that are present in the subcapsular sinus. Which o f these 
CCL21 gene products is expressed by collecting lymphatic vessels is not clear, b) 
Functional CCL19 expression by DC is abrogated in pit (paucity o f lymph-node T cells) 
mice. In addition, CCL21-Ser, but not CCL21-Leu, is absent. Peripheral DC migrate 
poorly to the T-cell zone of lymph nodes in pit mice, but some DC aberrantly 




The migration pathway that leads DC from periphery to secondary lymphoid organs is 
still poorly understood and may involve multiple signals in addition to CCR7. In a 
recent study it was proposed that CCR8 and its cognate ligand CCL1 are involved in the 
emigration of mouse monocyte-derived DC out of the skin. Furthermore, in vitro, the 
reverse transmigration of human monocyte-derived DC was significantly inhibited by 
the presence of blocking CCR8 antibodies. Since CCL1 is expressed in the subcapsule 
of the lymph nodes, it is possible that CCL1/CCR8 may function downstream of the 
entry of DC into the lymphatic by regulating the entry of the afferent DC in the 
subcapsular sinus of the lymph nodes (221). Expression of CXCR4, the CXCL12 
receptor, is retained during DC maturation and mature monocyte-derived DC were 
shown to migrate in response to CXCL12 (215), however, blood DC matured in vitro 
apparently do not express functional CXCR4 (222).
The relevance of chemotactic receptors in DC traveling in vivo has been clearly 
documented in mice lacking the gamma isoform of phosphoinositide-3 kinase (PI3Ky) 
(223). DC generated from PI3Ky null mice show a profound defect in the migration in 
response to both inflammatory and constitutive chemokines. A defect of DC migration 
was also observed in vivo in PI3Ky~/_ and most importantly, this defect was associated 
with a defective ability of PI3Ky_/_ mice to generate a specific immune response.
Overall these findings provide a model for DC trafficking in which activation of 
inflammatory chemokine receptors (e.g. CCR1, CCR2, CCR4, CCR5 and CCR6) 
function as signals to localize immature DC or their precursors to peripheral tissues. 
After Ag uptake, immune/inflammatory stimuli induce DC maturation and the loss of 
responsiveness to inducible chemokines locally produced. This unresponsiveness plays 
a permissive role for DC to leave peripheral tissues. Meanwhile the slower up 
regulation of CCR7, and possibly other chemotactic receptors, prepare DC to respond to 
CCL19 and CCL21 expressed in lymphoid organs.
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1.4.3.3 Migration of plasmacytoid dendritic cells
The expression of chemokine receptors on sorted blood myeloid DC and plasmacytoid 
DC is, in general, fairly similar (222). Both subsets express relatively high levels of CC 
chemokine receptor CCR2 and CXCR4. Whereas CCR1, CCR3, CCR4, CXCR1, 
CXCR2, CCR6 and CXCR5 are very weakly, or not expressed, on both circulating 
myeloid DC and plasmacytoid DC. Conversely, CCR5 and CXCR3 expression is 
clearly divergent in the two subsets, being low on blood myeloid DC, but high on 
plasmacytoid DC (222, 224). In contrast with the overall similar pattern of chemokine 
receptor expression, circulating myeloid DC and plasmacytoid DC exhibit a profound 
difference in their capacity to migrate in response to chemokines with CXCL12 being 
the only chemokine active in a classic chemotaxis assay (222) or in transmigration 
assays across an endothelial cell monolayer (225). In classical chemotaxis assays, the 
ligands of CXCR3, namely CXCL9, CXCL10 and CXCL11, are inactive in inducing 
plasmacytoid DC migration but can promote plasmacytoid DC migration in response to 
CXCL12 (226). However, it was shown that CXCR3 ligands are fully competent in 
inducing plasmacytoid DC adhesion and migration when presented to plasmacytoid DC 
immobilized on the heparan sulfates present on endothelial cells membrane, a 
physiological relevant condition (14).
1.4.3.4 Regulation of dendritic cell migration
Multiple evidences have shown that chemokine receptor expression is not predictive of 
DC migration suggesting that the coupling of chemokine receptors to chemotaxis is also 
regulated at the signaling level (Figure 1.16) (98, 222). For instance the simultaneous 
exposure of DC to maturation factors and anti-inflammatory cytokines (i.e. IL-10) 
uncouples inflammatory chemokine receptors from chemotaxis and converts them in 
scavenging chemokine receptors (98) Recent findings revealed that eicosanoids, such as
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cysteinyl leukotrienes (cysLTs) and prostaglandin E2 (PGE2) regulate CCR7-dependent 
migration of DC to lymph nodes (227). CysLTs derive from the 5-lipoxygenase (5-LO) 
pathway of arachidonic acid metabolism. Experimental evidence about the role of 
cysLTs in DC migration emerged by the use of MRP1 blocking antibodies and from 
studies in mice lacking the lipid transporter multidrug resistance protein 1 (MRP1) 
(228). In the absence of MRP 1 the migration of epidermal DC to the draining lymph 
node was impaired and the exogenous administration of LTC4 or LTD4 could rescue 
the defect. DC express the cysLTs receptor CysLTl, and in vitro, cysLTs promoted DC 
migration in response to the CCR7-ligands CCL19 and CCL21. Therefore, the MPR1- 
mediated efflux of cysLTs and autocrine or paracrine activation of cysLTR promote the 
migration of maturing DC.
MRP1
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Figure 1.16 Factors that regulate dendritic cell migration.
Several agonists are known to promote (CystLTs, SIP, PGE2, CD31), or inhibit (PGD2, 
LPXA4 and resolvin El) the migration of dendritic cells. A l, adenosine receptor A l; 
CystLTs, cysteinyl leukotrienes; SIP, sphingosine 1-phosphate; PGE2, prostaglandin 
E2; PGD2, prostaglandin D2; LPXA4, lipoxin A4.
Taken from Sozzani, S. 2005.Cytokine Growth Factor Rev (16)
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PGE2 is an arachidonic acid metabolite generated by PGE2 synthases downstream of 
cyclooxygenases. PGE2 modulates multiple aspects of DC biology, such as maturation, 
cytokine production, T cell activation and apoptosis (227). Furthermore, PGE2 
promotes the migration of mature human monocyte-derived DC to the CCR7 ligands 
CCL19 and CCL21 (229). The effect of PGE2 on these cells is mediated by two of the 
four PGE2 receptors, namely EP2 and EP4 and the cAMP pathway. Interestingly, blood 
myeloid (CDlb/c+) DC, matured in vitro, did not require PGE2 for an optimal 
migration in response to CCR7 ligands (230). These results suggest that the coupling of 
CCR7 to chemotaxis is regulated by the state of activation/maturation of DC. The 
importance of PGE2 for DC migration has been highlightened in vivo by the use of 
mice that are genetically defective for EP4 (231). Ptger4~h  mice displayed a reduced 
migration of skin Langerhans cells to regional lymph nodes after FITC sensitization, in 
vivo, and a reduced spontaneous emigration from skin explants, ex vivo. The 
nonredundant role of EP4 in Langerhans cell migration was further confirmed in wild- 
type mice by the use of an EP4 antagonist, and correlated with an impaired induction of 
contact-type hypersensitivity responses (231)
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2 Chapter 2. Materials and methods
2.1 Cell culture
2.1.1 Isolation of PBMC
PBMC were purified by Ficoll-Hypaque density centrifugation. Briefly, heparinised 
venous blood from healthy donors, or buffy coat (through the courtesy of the Centro 
Trasfusionale, Ospedale Civile Fomaroli, Magenta, Italy) was diluted 1:1 with sterile 
PBS (without Ca2+ or Mg2+; Gibco BRL, Paisley, UK) and centrifuged on Ficoll 
(Biochrom) for 30 minutes at 500 g. The mononuclear cell layer was removed using a 
sterile pipette, and washed thoroughly by resuspension in sterile PBS (Gibco BRL). The 
PBMC were then used for RNA extraction or monocyte isolation.
2.1.2 Isolation of monocytes
Isolation of monocytes from PBMC was performed using Percoll gradients (Pharmacia 
Fine Chemicals, Uppsala, Sweden). Briefly, PBMC resuspended in osmolarized RPMI 
were centrifugated on osmolarized Percoll diluted with osmolarized RPMI at the ratio 
for 30 minutes at 550 g. The monocyte monolayer was removed using a sterile pipette, 
and washed thoroughly by resuspension in sterile PBS (Gibco BRL). Purity of the 
monocyte population was always >95 % as assessed by flow cytometry using anti- 
CD 14 conjugated to FITC.
2.1.3 Generation of monocyte-derived dendritic cells
Monocytes were cultured for 6 days at 1 x 106/ml in six-well tissue culture plates 
(Falcon; BD Biosciences, Franklin Park, NJ) in RPMI 1640 supplemented with 10% 
FCS, 50 ng/ml GM-CSF, and 20 ng/ml IL-13. Where indicated, DC were further 
cultured in the presence of 100 ng/ml LPS and 20 ng/ml TNF for 48 h or as otherwise 
specified. CD40 ligand (CD40L)-transfected J558L cells or mock-transfected control
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cells were cultured with DC at a 1:4 ratio. Incubation of DC with the J558L mock- 
transfected cells did not induce cell maturation or chemokine production (data not 
shown).
2.1.4 Peripheral blood DC purification and culture
PBMC were isolated from buffy coats by Ficoll gradient (Pharmacia Biotec, Uppsala, 
Sweden), and peripheral blood myeloid (M-DC) and plasmacytoid (P-DC) DC were 
magnetically sorted with BDCA-1 and BDCA-4 cell isolation kits (Miltenyi Biotec, 
Bergisch Gladblach, Germany), respectively to a purity of 95-98%. Blood M-DC and P- 
DC (2 x 104 cells/well) were cultured in 96-well plates (Costar, Cambridge, MA) in 
RPMI 1640 culture medium supplemented with 5% FCS, 2 mM L-glutamine, 50 pg/ml 
gentamicin, 1 mM sodium pyruvate, and 1% nonessential amino acids plus 1000 U/ml 
GM-CSF and 10 ng/ml IL-4 (BD PharMingen, San Diego, CA) or 20 ng/ml IL-3 (BD 
PharMingen), respectively.
2.1.5 Cell lines and culture
The mouse LI.2 lymphoma cell line was grown in RPMI 1640 supplemented with 2 
mM L-glutamine, 1 mM sodium pyruvate, 10% FCS (HyClone Laboratories, Logan, 
UT), 10 mM Hepes pH 7.4, 50 pM 2-mercaptoethanol. Mouse lymphatic endothelial 
cells (MELC) were obtained following a previously described procedure (232). Briefly, 
hyperplastic vessels were induced by injection of IF A in DBA/2 mice and were isolated 
from liver and diaphragm. After collagenase treatment, the single cell suspension was 
cultured at 37°C and 5% CO2 in gelatin-treated plastic dishes in DMEM (Life 
Technologies) supplemented with 10% FCS, 10% sarcoma 180 cell-conditioned 
medium, 1 mM sodium pyruvate, 100 pg/ml heparin, 100 pg/ml endothelial cell growth 
supplement, and antibiotics. CHO-K1 cells were cultured in DMEM-HAM F12 medium 
supplemented with 2 mM L-glutamine, 10% FCS, 10 mM Hepes pH 7.4.
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2.2 Cell transfectants
2.2.1 cDNA cloning
The human CCRL2A and B coding sequences were amplified by PCR from genomic 
DNA using standard methodology and cloned into the pcDNA3 mammalian expression 
vector (Invitrogen, Carlsbad, CA). The insert was fully sequenced and shown to be 
identical to Gene Bank sequence xxx
2.2.2 Cell transfection
The mouse L1.2 lymphoma cell line was transfected by electroporation with linearized 
CCRL2A and B/pcDNA3 and selected with 800 pg/ml G418 (Life Technologies), 
resistant cells were cloned by limiting dilution. Chinese hamster ovary (CHO)-Kl cells 
were transfected with CCRL2A and B/pcDNA3 with lipofectamine 2000 (Invitrogen), 
selected with 500 pg/ml G418 and cloned by limiting dilution. D6/L1.2 and D6/CHO- 
K1 transfectants were obtained as previously described (108), CCR4/L1.2 were a kind 
gift of Dr. Daniele D’Ambrosio (BioXell, Milan, Italy). Clones MELC-2 and 
D6/MELC-2, selected for these studies, have been described previously (108). CCR4- 
D6/L1.2 were obtained transfecting CCR4/L1.2 with the plasmid D6/pcDNA6 encoding 
the HA-tagged human D6 receptor, and selected for the stable expression of both 
receptors in growing medium in the presence of hygromycin and G418
2.3 Methods for analysing RNA expression
2.3.1 RNA extraction
Total RNA was prepared from all samples using TRIZOL® Reagent (Invitrogen) 
according to the manufacturer’s instructions. Briefly, 5-10x106 cells were centrifugated 
and pellet was lysed with 1 ml of TRIZOL® by repetitive pipetting. Samples were 
incubated for 5 minutes at 15 to 30°C to permit the complete dissociation of 
nucleoprotein complexes and 0.2 ml of chloroform per 1 ml of TRIZOL was added. 
Samples were shaken vigorously by hand for 15 seconds and then incubated at 15 to
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30°C for 2 to 3 minutes. Samples were centrifugated the samples at 12,000 x g  for 15
minutes at 2 to 8°C. Following centrifugation, the mixture separates into a lower red,
phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. RNA
remains exclusively in the aqueous phase. The volume of the aqueous phase is about
60% of the volume of TRIZOL Reagent used for homogenization. The aqueous phase is
transferred to a fresh tube, and RNA was precipitated from the aqueous phase by mixing
with isopropyl alcohol (0.5 ml of isopropyl alcohol per 1 ml of TRIZOL Reagent used
for the initial homogenization). Samples were incubated at 15 to 30°C for 10 minutes
and centrifugated at 12,000 x g for 10 minutes at 2 to 8°C. The RNA precipitate, often
invisible before centrifugation, forms a gel-like pellet on the side and bottom of the
tube. After having removed the supernatant, the RNA pellet was washed once with 75%
ethanol, adding at least 1 ml of 75% ethanol per 1 ml of TRIZOL Reagent used for the
initial homogenization. The sample was shaked by vortexing and centrifugated at no
more than 7,500 x g for 5 minutes at 2 to 8°C. At the end of the procedure, briefly the
RNA pellet was dried (air-dry or vacuum-dry for 5-10 minutes). It is important not to let
the RNA pellet dry completely as this will greatly decrease its solubility. RNA was
dissolved in RNase-free water by passing the solution a few times through a pipette tip,
and incubating for 10 minutes at 55 to 60°C. For RT-PCR, total RNA was DNase-
treated to remove contaminating genomic DNA, using RNase-free DNase I (Pharmacia
Biotech, St. Albans, UK).
2.3.2 RT-PCR
2.3.2.1 cDNA synthesis
cDNA was synthetised from 5 pg of DNase-treated total RNA using the Superscript. Ill
First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer’s
instructions. Briefly, the volume of 5 jag of DNase-treated total RNA was adjusted to 8
pi with DEPC-treated water, and 1 pi of oligo dT/random examers 50 pM and 1 pi of
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dNTPs lOmM were added. The RNA was incubated at 65 °C for 5 min, then on ice for 
at least 1 min. Then 10 pi of cDNA Synthesis Mix (10X RT buffer 2 pi, 25 mM MgC12 
4 jil 40, 0.1 M DTT 2 pi, RNaseOUT. (40 U/pl) 1 pi, Superscript. Ill RT (200 U/pl) 1 
pi) were added to each sample, mixed gently and collected by brief centrifugation. 
Tubes were incubated for 50 min at 50°C, then at 85°C for 5 min and chilled on ice in 
order to terminate reaction. 1 pi of RNAse H was added to each tube and incubated for 
20 minutes at 37°C, cDNA synthesis reaction can be stored at -20°C or used for PCR. 
2pl (equivalent to 200 ng of total RNA) were used for PCR.
2.3.2.2 Primers
The primers for CCRL2 were designed from sequences submitted to Genbank. The 
primer sequences and product size are: forward gatgaggcagagcaatgtga; back 
ggcagggtaagcaagaaaca; product size: 209 bp. The ‘housekeeping’ gene p-actin was used 
in all PCR reactions to control for reverse transcription of the total RNA.
2.3.2.3 Polymerase chain reaction (PCR)
PCR was performed using a GeneAmp® PCR System 9700 thermal cycler (Perkin 
Elmer, Beaconsfield, UK). For each primer pair, a master mix was prepared containing 
all reagents except for the cDNA. The final volume of each PCR reaction was 25 
pi,containing 200 ng cDNA, 1 U AmpliTaq DNA polymerase, GeneAmp PCR buffer, 
GeneAmp dNTPs (all from Perkin Elmer) and 4 pM each primer. The following 
protocol was used for the PCR reaction: 94 °C (5 min); 35 cycles 94 °C (30 s), 60 °C 
(30 s), 72 °C (30 s); 72 °C (7 min). 15 pi of each PCR reaction was added to 5 pi of 
loading buffer and electrophoresed through a 1.2 % agarose gel containing 0.5 pg/ml 
ethidium bromide (Sigma). Bands were visualised by UV transillumination and their 
sizes were estimated using a co-migrated DNA size marker (123 bp marker; Gibco
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BRL, Paisley, UK). PCR products were gel extracted (QiaQuick Gel Extraction kit, 
Qiagen, UK) and sequenced to confirm their identity.
2.3.2.4 Real-time PCR 
Real-time PCR was done with SYBR Green dye and GeneAmp 5700 Sequence 
Detection System (PE Biosystems, Foster City CA). The sequences of primer pairs 
specific for each gene (Invitrogen, Milan, Italy) were designed with Primer Express 
Software (Applied Biosystems). Two pi of cDNA were used as the template; 12.5 pi of 
2x SYBR Green PCR Master Mix (Applied Biosystems) were mixed with template and 
primers. The total reaction volume was 25 pL. Cycling conditions were 10 minutes at 
95°C, 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Experiments were done in 
triplicate for each sample. Absolute quantification was performed using standard curves 
for both CCRL2 and p-actin plasmids. Extrapolated number of CCRL2 copies of 
mRNA were normalized to 106 copies of B-actinmRNA.
2.3.3 Northern blotting
2.3.3.1 cDNA probes 
cDNAs for CCRL2A and p-actin were obtained from expression plasmids. Appropriate 
restriction enzymes were used to cut out each cDNA insert of CCRL2A and B-actin; 
each digest reaction was added to 5 pi of loading buffer (40 % w/v sucrose; 0.25 % w/v 
bromophenol blue; 0.25 % xylene cyanol [all from Sigma, Poole, UK]; made up in 
distilled water) and electrophoresed through a 1 % agarose gel containing 0.5 pg/ml 
ethidium bromide. Insert cDNA bands were visualised by UV transillumination and gel 
extracted (QiaQuick Gel Extraction kit, Qiagen, UK). The purified cDNA insert was 
subsequently used for probe labelling (Section 2.4.4.iii).
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2.3.3.2 Northern blotting
10 fag of total RNA was mixed with 5 (al of loading buffer (48 % deionised formamide 
[Gibco BRL, Paisley, UK], 6 % formaldehyde [Merck/BDH, Lutterworth, UK], 5 % 
glycerol, 20 mM MOPS [3-TV-morpholinopropanesulphonic acid], 5 mM sodium acetate 
and 1 mM EDTA pH 8.0 [all from Sigma, Poole, UK] made up in DEPC-treated water). 
Each RNA sample was heated to 65 °C for 5 minutes, then placed on ice prior to 
loading. The RNA was subjected to electrophoresis through a 1 % agarose- 
formaldehyde gel (1 % agarose [Gibco], 6 % formaldehyde, 20 mM MOPS, 5 mM 
sodium acetate, 1 mM EDTA pH 8.0, 0.5 pg/ml ethidium bromide) then blotted by 
capillary transfer onto nylon membrane (Hybond N+, Amersham, UK). After transfer, 
the membrane was UV crosslinked (1200 J) in a Stratalinker (Stratagene, La Jolla, CA, 
USA).
2.3.3.3 Probe labelling and hybridisation
The membrane was placed in a suitable hybridisation tube and pre-hybridised for 1-2 
hours at 42 °C with 20 ml of hybridisation buffer (0.2 M sodium phosphate buffer pH 
7.2, 1 mM EDTA pH 8.0, 1 % BSA, 7 % SDS, 45 % formamide, made up in distilled 
water). cDNA probes were labelled by random priming using the Stratagene Prime-It II 
kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions. 
Unincorporated [<32P]CTP nucleotide was removed by passing the radiolabelled probe 
through a Clontech Chromaspin TE 100 spin column (Clontech, Basingstoke, UK), 
following the manufacturer’s instructions. Prior to use, the radiolabelled probe was 
heated to 100 °C for 5 minutes, then quenched on ice for up to 30 min. Probe was then 
added to 20 ml of hybridisation buffer (approximately 1 x 106cpm/ml of buffer), which 
was poured on to the membrane in place of the pre-hybridisation buffer. Hybridisation 
was performed overnight at 42 °C. Following hybridisation, membranes were washed
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twice with 2 x SSC, 0.1 % SDS for 5 min at room temperature, twice with 0.1 x SSC, 
0.1 % SDS for 15 min at 68 °C and finally once with 2 x SSC for 10 min at room 
temperature. The membrane was then wrapped in Saran wrap and exposed overnight to 
Kodak Biomax MS film with an intensifying screen, at -70 °C. Densitometry was 
performed using NIH Image 1.61. Radiolabelled probe was stripped from the membrane 
by washing the membrane in boiling 0.1 % SDS. The membrane was left on a shaker 
until the solution cooled down; it could then be re-probed.
2.4 Flow cytometry
2.4.1 Monoclonal antibodies
Monoclonal anti-human CCRL2A/B antibody (catalog number: MAB2350 clone: 
152211) was from R&D System (Minneapolis, MN). This antibody was produced from 
a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a 
mouse immunized with NS0 cells transfected with CCRL2A isoform. The IgG fraction 
of the tissue culture supernatant was purified by Protein G affinity chromatography. It 
detects both the CRAM-A and CRAM-B isoforms. Monoclonal anti-human D6 (Clone 
196124) and anti-CCR4 (Clone: 205410) antibodies were from R&D System.
2.4.2 Immimofluorescent staining protocol
For staining, cells were washed in PBS supplemented with 1 % BSA and 0.01 % NaN3 
(FACS buffer). Approximately 5 x 105 cells were resuspended in 200 pi of FACS buffer 
in a microfuge tube, then 10 pg of human IgG was added to block Fc receptors. After 15 
min incubation at room temperature, primary antibody was added to a final 
concentration of between 2-20 pg/ml. Cells were incubated with the primary antibody 
for 30 min on ice. The cells were then washed twice by addition of 1 ml of cold FACS 
buffer, centrifugation at 13,000 rpm for 10 seconds in a microfuge at 4 °C, and 
resuspension in cold FACS buffer. Cells stained with FITC- or PE-conjugated
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antibodies were then ready for flow cytometric analysis. For unconjugated antibodies, 
cells were resuspended in 200 pi of FACS buffer and FITC-conjugated secondary 
antibody was added (at an appropriate dilution). Following a further 30 minute 
incubation on ice, the cells were washed twice as before, then analysed by flow 
cytometry. For two-colour flow cytometry, cells were incubated with the first antibody, 
washed, then incubated with the second antibody, washed, and analysed. Cells were 
analysed on a FACScan® flow cytometer using Cellquest software (Beckton Dickinson, 
Oxford, UK).
2.5 Measurement of intracellular Ca 2+ concentration
Changes in [Ca2+], were monitored using the fluorescent probe fura-2 according to the 
technique reported by Grynkiewicz et al. (233). Briefly, cells (107/ml) were resuspended 
in RPMI 1640 and incubated with 1 pM fura-2 acetoxymethyl ester (Calbiochem, San 
Diego, CA) at 37°C for 20 min. After incubation, cells were washed and resuspended in 
HBSS (Biochrom) containing 1.2 mM CaCI, and kept at room temperature until used. 
Fura-2 fluorescence was measured in a Perkin-Elmer LS 5 0B spectrophotometer 
(Perkin-Elmer Instruments, Norwalk, CT) at 37°C with cells (3-5 X IOVml) 
continuously stirred. Samples were excited at 340 and 380 nm, and emission was 
continuously recorded at 487 nm.
2.6 Chemotaxis
Migration of D6/L1.2 and CCR4/L1.2 cells was evaluated using 5 pm pore size 
Transwell filters (Coming Costar, Cambridge, MA). 600 pi of binding buffer 
supplemented with different concentrations of chemokines were placed into the lower 
chamber. CCRL2A/B 11.2, D6/L1.2 or CCR4/L1.2 cells were resuspended in the same 
buffer at the concentration of 1 x 107 cells/ml, and 100 pi of cell suspension were placed 
onto the upper chamber. After 4 h of incubation at 37°C and 5% CO2, the upper
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chamber was removed and the cells in the lower chamber were counted in a Btirker 
chamber.
2.7 Binding
CCL2 competitive binding was performed by incubating 7.5 x 105 D6/L1.2 cells with 
50 pM I-CCL2 in the presence of different concentrations of nnlabeled CCL2, CCL4, 
CCL17, CCL19 or CCL22 in 200 pi binding buffer (RPMI 1640, 4 mM Hepes pH 7.4, 
1% BSA) at 4°C for 2 h. After incubation, the cell-associated radioactivity was 
measured. To estimate the IQ (i.e. the equilibrium dissociation constant) and the Bmax 
(i.e. the maximum number of binding sites), CCL2 homologous competitive binding 
data were analyzed by non-linear fitting using the equation of the "homologous 
competitive binding curve" (GraphPad Prism 3.0a; GraphPad Software Inc., San Diego, 
CA). Inhibition curves were analyzed using the equation of the "one site competitive 
binding equation" (GraphPad Prism 3.0a) to estimate the IC50 value, from which the Ki 
value was then calculated according to the Cheng-Prusoff equation (234).
2.8 Chemokine scavenging
D6/CHO-K1 (2 x 105), D6/MELC-2 (1 x 105) or D6/L1.2 (1 x 106) cells were incubated 
for indicated time periods at 37°C in 200 pi of binding buffer supplemented with 1.2 
nM of indicated chemokine. At the end, the chemokine concentration in the supernatant 
was measured by specific ELISA (R&D Systems).
2.9 Receptor internalization.
CCR4/L1.2 or D6/L1.2 cells were resuspended at 5 x 106 cells/ml in binding buffer and 
incubated with the appropriate receptor-specific primary antibody at 4°C for 1 h. After 
washing in ice-cold PBS containing 1% FCS, cells were incubated for various times at 
37°C in the presence or absence of 60 nM CCL22. After washing in ice-cold PBS 
containing 1% FCS and 1% sodium azide, cells were incubated at 4°C with fluorescein
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isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Jackson Laboratories) for the 
anti D6 monoclonal antibody or streptavidin - FITC for the anti-CCR2 antibody, 
respectively. In recycling experiments, cells were restained with the primary antibody 
after the internalization step and before the labeling with the appropriate secondary 
antibody was performed as described above. After staining, cells were resuspended at 5 
x 105/ml in ice-cold PBS containing 1% FCS and 1% sodium azide and analyzed in a 
FACSCalibur™ flow cytometer (BD Biosciences) and data were analyzed with 
CellQuest software (BD Biosciences). Relative receptor surface expression was 
calculated as 100x [mean channel of fluorescence (stimulated) - mean channel of 
fluorescence (negative control)/mean channel of fluorescence (medium) - mean channel 
of fluorescence (negative control)] (%). LI.2 cells not expressing D6 or CCR4 and 
irrelevant monoclonal antibodies were used for negative controls with similar results.
2.10 Statistical analysis
Standard deviations were calculated and statistical significance assessed by Student t 
test for paired samples. Values of p < 0.05 were considered to be significant.
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3 Chapter 3. CCRL2 expression in tissues and 
leukocytes
3.1 Introduction
A small number of orphan receptors, presenting structural similarities with known 
chemokine receptors, still await functional characterization. Among these CCRL2 is an 
interesting candidate as it shares over 40% amino acid identity with CCR1, CCR2, 
CCR3 and CCR5. Furthermore its gene is located in the main cluster of CC-chemokine 
receptor genes in the 3p21-23 region, together with CCR1 to 5, CCR8 to 10, XCR1 and 
CX3CR1 (235)
The functions of a given receptor are dictated by its expression pattern across leukocyte 
subclasses, the regulation of its expression as well as the regulation of the expression of 
the chemokines acting on this receptor. Determining the distribution and regulation 
patterns of an orphan receptor may therefore greatly contribute to the understanding of 
its potential roles. It may also allow us to tentatively classify the receptor as responding 
to inflammatory or constitutive chemokines, and may raise hypotheses regarding its 
contribution to the various steps of an immunological response. Finally it may suggest 
in which tissues and conditions the cognate ligand(s) should be searched for.
CCRL2 was first cloned from a human neutrophil cDNA library (134), and data 
obtained by Northern blotting showed expression in lymphoid (spleen, lymph node, 
fetal liver, bone marrow) and non-lymphoid (lung, heart) organs (134).
3.2 Aim of the chapter
The aim of this chapter was to examine the expression of CCRL2 in different tissues 
and main circulating leukocyte populations. The subsequent aim was to study the 
regulation of CCRL2 expression in DC.
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3.3 Results
3.3.1 CCRL2 expression in tissues
CCRL2 tissue expression was assessed by mean of a commercial multiple tissue array 
(Clontech) containing polyA+ RNA from 76 different human tissues. Densitometric 
analysis (Figure 3.1) revealed that CCRL2 transcripts were present at highest levels in 
lung and fetal spleen while moderate levels were present in bone marrow, testis, fetal 
liver, lymph node, spleen, fetal lung, the descending part of the colon, mammary gland 
and fetal thymus. Low levels of CCRL2 were also detectable in brain (cerebellum), 
heart, ilocecum, thymus, placenta, and liver. All the other tissues present on the array 
did not express CCRL2 transcripts. As previously reported by others (134), this analysis 
suggests that CCRL2 is highly expressed in almost all lymphoid tissues; however our 
results show highest levels of transcript in lung and fetal tissues suggesting a specific 
role for this receptor during embryogenesis.
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Figure 3.1. CCRL2 expression in human tissues.
Multiple tissue array (Clontech) was hybridized with CCRL2 specific probe. Results 
shown were obtained from densitometric analysis o f one autoradiography.
3.3.2 CCRL2 expression in leukocytes
To study CCRL2 expression in leukocyte subsets, real-time quantitative polymerase 
chain reaction was performed with T naive, T h l, Th2, T el, Tc2 and B lymphocytes, NK 
cells, immature and mature DC (treated 4 hours with LPS). Mature dendritic cells 
expressed the highest copy number o f CCRL2 molecules, while the remaining 
leukocytes analyzed expressed low levels o f CCRL2 transcript (Figure 3.2). In 
agreement with previous results (236) resting monocytes and neutrophils expressed 
CCRL2 transcripts as assessed with Northern blot analysis (Figure 3.3). FACS analysis 
on peripheral blood mononuclear cells (PMBC) labeled with a monoclonal antibody
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against CCRL2, indicated that almost 50% of monocytes were CCRL2 positive while 
only 15% of lymphocytes expressed the receptor (Figure 3.4). Our analysis suggests 
that CCRL2 expression is restricted to cells o f the myelomonocytic lineage and 
indicates that CCRL2 expression is strongly up-regulated in dendritic cells after 
maturation.
OJ 1 0 0 0 0  1
u  T naive Th1 Th2 Tc1 Tc2 NK B DC-IMM D C -L PS
Figure 3.2. CCRL2 expression in human leukocytes.
Real-time quantitative PCR was performed with cDNA obtained from the 
retrotranscription of 2 pg o f RNA of the indicated leukocytes. Results shown were 
obtained from statistical analysis o f three different experiments. Absolute quantification 
was performed using standard curves for both CCRL2 and (3-actin.
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Figure 3.3 CCRL2 expression in human monocytes, neutrophils.
10 (ng o f total RNA were purified from monocytes and PMN obtained from buffycoats 
o f healty donors and used in Northern blot analysis with CCRL2 probe. The 
autoradiography shown was obtained after 12 h of exposure. Etidium bromide staining 
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Figure 3.4 CCRL2 expression in human leukocytes.
Human PBMCs were isolated as described in Materials and methods and stained for 
CCRL2 expression. PBMC subsets were analyzed by FACS analysis. One experiment 
representative of four independent ones is shown. Each panel contains the percentage of 
positive cells and the mean fluorescence intensity o f CCRL2 expression. R l: 
monocytes, R2: lymphocytes.
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3.3.3 Regulation of CCRL2 expression in DC
CCRL2 over-expression in monocyte derived DC (Figure 3.2) was also investigated at 
the protein level. DC were differentiated in vitro from blood monocytes (>95% CD14+), 
obtained by Ficoll and Percoll gradients. Monocytes were cultured for 6 days with GM- 
CSF and IL-13 and then FACS analysis was performed in order to assess the correct DC 
differentiation. As depicted in Figure 3.5, at the end of the culture cells were 90% CDla 
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Figure 3.5 Phenotype of immature DC
Monocytes after 6 days of culture in the presence of 50 ng/ml GM-CSF and 10 ng/ml 
IL-13 were subjected to FACS analysis for C D la, CD 14, MHCII and CD83 expression 
using specific monoclonal antibodies. Each panel contains the percentage o f CCRL2 
positive cells. One experiment representative o f four independent ones is shown.
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DC maturation was obtained by stimulation with LPS, TN F-a or admixing with the 
irradiated cell line J558 CD40L-transfected for 4 hours. Figure 3.6 showed that all 
stimuli tested were able to induce DC maturation, as assessed with FACS analysis for 
CD83 protein expression. CD83 was not expressed by immature DC while was strongly 
upregulated by all the maturative stimuli used. Incubation of DC with the J558 mock 
cell line did not induce cell maturation (data not shown).











Figure 3.6 Upregulation of CD83 expression by maturative stimuli.
Immature DC were cultured in the presence of LPS (100 ng/ml), TN F-a (50 ng/ml) and 
CD40L (5:1, DC:CD40L-transfectants) for 4 hours and then subjected to FACS analysis 
for CD83 expression by the use o f a monoclonal antibody. Each panel contains the 
percentage o f positive cells and the mean fluorescence intensity o f CCRL2 expression. 
The figure shows a representative experiment o f three performed with similar results
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Northern blot experiments revealed that in immature DC CCRL2 expression varied 
among donors (data not shown). However stimulation with maturative stimuli like LPS 
(lOOng/ml) and CD40L expressing cell line (1:5) for 4h up regulated CCRL2 expression 
o f 28.5 ± 7.9 fold (n=4) and 18.8 ± 10.9 fold (n=2) respectively, over the control 
evaluated with densitometrical analysis. In an opposite way stimulation for the same 
time with TN F-a (50 ng/ml), a cytokine able to induce DC maturation, had no effect on 
CCRL2 basal expression (Figure 3.7A). Upregulation o f CCRL2 expression by LPS 
was then measured at protein level by FACS analysis. As shown in figure 3.7B 35% of 
immature DC expressed CCRL2 while after LPS stimulation the percentage o f CCRL2 
positive cells raised to 70%.
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Figure 3.7 CCRL2 expression in human dendritic cells.
A 10 pg o f total RNA were purified from DC incubated for 4h in the presence or 
absence o f LPS (100 ng/ml), TN F-a (50 ng/ml) and CD40L (5:1, DC:CD40L- 
transfectants) and used in Northern blot analysis. B Immature DC and DC stimulated 
with LPS were subjected to FACS analysis for CCRL2 expression by the use o f 
monoclonal antibody. Each panel contains the percentage of positive cells and the mean 
fluorescence intensity of CCRL2 expression. The figure shows a representative 
experiment o f three performed with similar results
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In order to understand if CCRL2 mRNA upregulation was associated with DC 
maturative process, we cultured DC in the presence of inhibitors of maturation and 
function. Figure 3.8 panel A shows that both VitD3 (10-7 M) and Dex (10'5 M), two 
drugs able to block DC maturation in terms of CD83 expression and cytokine 
production (IL-12) had no effect on LPS-induced CCRL2 up regulation; on the contrary 
PGE2 (10'5 M), that does not affect DC maturation but similarly to VitD3 and DEX is 
able to inhibit IL-12 production, completely abolished LPS effect on CCRL2 
expression. These compounds had no effect on CCRL2 basal expression (data not 
shown). Figure 3.8 B shows the mean of densitometric analysis of 4 Northern blot 
experiments in which cells were treated for 4h as indicated. LPS induced an increase of
28.5 ± 7.9 fold (p<0.001 by paired Student's T-test) fold over control. When DC were 
stimulated with LPS together with PGE2 CCRL2 expression was reduced to 0.97 ± 0.3 
(p<0.001) fold over the control, while stimulation with LPS together with DEX and 
VitD3 did not inhibit CCRL2 up regulation (24.7±17.6 and 54.8±24.2, respectively, over 
the control). Thus, these results indicated that only PGE2 is able to reverse the 
stimulatory effect of LPS.
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Figure 3.8 Effect of DEX, PGE2, VitD3 on CCRL2 expression in LPS stimulated 
DC.
A Northern blot analysis was performed with 10 pg o f total RNA purified from DC 
incubated for 4h in the presence or absence of LPS (100 ng/ml) and in combination with 
DEX (10“6 M), PGE2 (10“5 M) and VitD3 (10-7 M). Results are representative o f at 
least three different cell preparations. Autoradiographies shown were obtained after 12 h 
o f exposure. Etidium bromide staining is reported below. B Mean o f the densitometric 
analysis of four different experiments.
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Figure 3.9 shows that the effect o f LPS on CCRL2 expression by DC was detectable 
after 1.5 h stimulation, reached a maximum at 4 h and was completely abolished at 24h. 
In a similar way, when DC were stimulated with CD40L-transfected cell line, CCRL2 
expression was upregulated following 4h stimulation but not at 24h. In the same 
experimental conditions CCR7 was strongly up regulated only after 24h stimulation 
with both LPS and CD40L, in agreement with previous published results (185).
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Figure 3.9 Time-course of CCRL2 expression in LPS and CD40L stimulated DC.
DC were incubated for different times with LPS (100 ng/ml) or with CD40L (4:1, 
DC:CD40L-transfectants) as indicated. 10 pg of total RNA were used in Northern blot 
analysis. Results o f one experiment, representative of two performed are shown. 
Autoradiographies were obtained after 12 h of exposure. Etidium bromide staining of 
the membrane is shown in the lower part o f the figure.
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3.3.4 CCRL2 expression in plasmacytoid dendritic cells
In order to understand whether CCRL2 expression was restricted to myeloid DC, RT- 
PCR analysis was performed on RNA extracted from blood DC subsets isolated on the 
basis of the expression o f specific membrane markers BDCA-1 for myeloid-DC and 
BDCA-4 for plasmacytoid-DC. Figure 3.10A shows that the CCRJL2 transcript was 
present in both subsets. FACS analysis for hCCRL2 showed that it was expressed by -  
40% of the circulating mDC population and by virtually all pDC.
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Figure 3.10 Expression of CCRL2 in blood DC subsets.
Blood DC subsets were isolated as described in materials and methods A. 2pg o f total 
RNA were used in RT-PCR experiment using specific primers for CCRL2 and (3-actin. 
(-: negative control, 1: P-DC, 2: M-DC, 3: circulating monocytes, 4: monocyte derived 
DC. Ethidium bromide staining for both genes is shown. B. Blood DC subsets were 
stained for CCRL2 expression with a monoclonal antibody. Data are representative o f at 
least two different experiments performed with independent donors. Thin lines represent 
negative control, bold lines represent CCRL2 staining.
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3.4 Discussion
To gain insight into the putative biological role of CCRL2, its expression was 
investigated in a variety of tissues and specific cell types. Over all tissue expression 
demonstrate that CCRL2 is highly expressed in fetal tissues, suggesting a role in 
embryogenesis. Furthermore it is highly expressed by both adult and fetal lung and, in 
this context, recent results published by Oostendorp et al. (237) suggest a specific role 
for murine CCRL2 in a model of ovalbumin (OVA)-induced airway inflammation. 
CCRL2 is also expressed by adult tissues where hematopoiesis occurs like bone 
marrow, lymphatic tissues, fetal spleen and fetal liver.
Analysis of leukocytes has revealed a unique profile for CCRL2. It is expressed by 
neutrophils and monocytes, as other inflammatory chemokine receptors. Interestingly it 
is also highly expressed by mature DC, a characteristic shared with the homeostatic 
chemokine receptor CCR7. Moreover inflammatory chemokine receptors like CCR1, 
CCR2 and CCR5 are downregulated during DC maturation while CCRL2 is rapidly and 
transiently upregulated, suggesting a function between the recruitment of leukocytes to 
inflammatory sites, and their redirection to lymphoid organs. Moreover the important 
up-regulation of CCRL2 following stimulation by CD40L suggests a possible role in 
DC-T cell interaction.
Data presented in this chapter indicate that CCRL2 upregulation by LPS is not part of
DC maturation because it is not reversed by coincubation of DC with inhibitors of
maturation process like VitD3 and DEX. Conversely PGE2, an arachidonic acid
metabolite that plays an essential role in DC migration to draining lymph nodes,
completely abolishes LPS-induced CCRL2 upregulation. The role of PGE2 in regulating
DC migration is still controversial: it appears from in vitro and in vivo data that PGE2
has a dual role in supporting migration of DC (229, 238), (230) regulating the
expression and the activity of CCR7. Our data suggest that the downregulation of
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CCRL2 by PGE2 may be involved in the effective migration of DC to the two CCR7 
ligands.
Plasmacytoid DC secrete high levels of type I interferon following activation. The 
production of type I interferon is believed to play a crucial role in anti-viral immune 
responses and in the activation of other leukocyte populations, like B lymphocytes and 
NK cells. Plasmacytoid DC are normally absent from peripheral tissues and they are 
believed to migrate constitutively from the blood to the lymph nodes, through high 
endothelial venules (17). Recruitment of plasmacytoid DC to non-lymphoid tissues is 
observed in some pathological conditions, such as autoimmune diseases, allergic 
diseases and in tumors (16). However, the mechanisms leading to the recruitment of 
plasmacytoid DC to inflammatory sites remain unresolved.
Blood myeloid DC and plasmacytoid DC express similar pattern of chemokine 
receptors but they exhibit a profound difference in their capacity to migrate in response 
to chemokines with CXCL12 being the only chemokine active in a classic chemotaxis 
assay or in transmigration assays across an endothelial cell monolayer (225). In classical 
chemotaxis assays, the ligands of CXCR3, namely CXCL9, CXCL10 and CXCL11, are 
inactive in inducing plasmacytoid DC migration but can promote plasmacytoid DC 
migration in response to CXCL12 (226, 239). However, it was shown that CXCR3 
ligands are fully competent in inducing plasmacytoid DC adhesion and migration when 
presented to plasmacytoid DC immobilized on the heparan sulfates present on 
endothelial cells membrane, a physiological relevant condition (14, 224, 240). For all 
these reasons the full characterization of chemoattractant receptors expressed by 
plasmacytoid DC versus myeloid DC will help in the understanding the different 
migratory capacity of this subset. Our results indicate that P-DC express CCRL2 both at 
protein and mRNA level. It will be helpful to study CCRL2 regulation by inflammatory 
stimuli in pDC.
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Finally our analysis reveals that CCRL2 is not expressed by T or B-lymphocytes and by 
NK cells. These results are different from data published by Migeotte et al. (138) that 
reports CCRL2 expression on the majority of T lymphocytes and on the majority of 
natural killer cells.
Conclusions from this chapter:
• CCRL2 is expressed by different tissues: lung, fetal spleen and lymphoid tissue.
• Among leukocytes CCRL2 is expressed by monocytes, dendritic cells and 
neutrophils
• CCRL2 expression in DC is up regulated by maturative stimuli like LPS and 
CD40L
• CCRL2 upregulation is reversed by PGE2 costimulation
• The upregulation of CCRL2 by LPS and CD40L is transient and 
complementary to CCR7 induction.
• CCRL2 is expressed by both plasmacytoid and myeloid DC
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4 Chapter 4. Generation of CCRL2 transfectants and 
screening for CCRL2 agonists
4.1 Introduction
The general strategy for the identification of ligands for orphan GPCRs is the use of a 
recombinant assay system. Following receptor expression, candidate ligands are 
screened against the receptor to identify molecules capable of specific regulation of that 
receptor. Such ligands can include tissue extracts, expressed or purified proteins or 
small peptides, natural and synthetic small molecules, and lipids.
It is important to choose of the right expression system and to find the best conditions to 
use for the screening because the success of this kind of experiment is entirely 
dependent upon the receptor being expressed at the cell surface and being able to couple 
to the signal transduction machinery of that cell. For these reasons it is not sufficient to 
demonstrate the presence of mRNA in the cell that is indicative of receptor expression 
but it does not always follow that receptor protein is expressed or is indeed at the cell 
surface. So it is important to use an antibody to demonstrate the presence and site of 
receptor expression through the use of studies such as fluorescence activated cell sorting 
(FACS) (241).
CCRL2 was transfected in two different cell lines, CHO-K1 and LI.2, that are 
frequently used to test chemokine receptor functions. As described in the introduction, 
phylogenetic analysis of GPCR receptor relationships suggested that CCRL2 constitutes 
a separate branch related to the chemokine receptors CCR1, 2, 3 and 5 and for this 
reason the analysis presented in this chapter was focused on CC chemokines (242).
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4.2 Aim of the chapter
This chapter describes the generation of CCRL2 transfectants and their use in screening 
assays such us chemotaxis and calcium fluxes.
4.3 Results
4.3.1 Analysis of CCRL2 A and B receptor variants
CCRL2 cDNA was cloned by three different groups and deposited in Gen-Bank under 
different names. We observed that one of these sequences, named CRAM-A (accession 
n°AF015524), differed from the others named CCRL2B (NM_003965), CRAM-B 
(AFO15525) and CRKX (U95626), in the deduced protein sequence by the presence of 
12 additional amino acid at its N-terminus as shown in Figure 4.1. Comparison of the 
CRAM-A and CCRL2 sequences with the sequences from an extended region of 
chromosome 3 revealed that the 70 bp insertion in CRAM-A was due to alternative 
mRNA splicing as shown in Figure 4.2. The predicted initiation codon of CRAM-A was 
within an exon 360 bp upstream from the major coding exon. In the genomic sequence 
the 70-bp fragment found in CRAM-A was delineated by the canonical intronic splice 
acceptor and splice donor dinucleotides. These observations suggested the existence of 
two different proteins differing in their N-terminus and hence in their ligand selectivity 
or affinity, because this part of the receptor is important for ligand binding. The possible 
presence of two alternative transcripts suggested another level of regulation for this 
gene; for other chemokine receptors this mechanism is known to extend the range of 
concentrations over which a cell can respond (243). Due to these observations we 
decided to clone both variants.
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N M _003965  -------------------------- MANYTLAPEDEYDVLIEGELESDEAEQCDKYDAQALSAQLVPSLCSAV 4 8
A F 0 1 5 5 2 4  MIYTRFLKGSLKMANYTLAPEDEYDVLIEGELESDEAEQCDKYDAQALSAQLVPSLCSAV 60
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
NM_0 0 3 9 6 5  FVIGVLDNLLWLILVKYKGLKRVENIYLLNLAVSNLCFLLTLPFWAHAGGDPMCKILIG 1 0 8
A F 0 1 5 5 2 4  FVIGVLDNLLWLILVKYKGLKRVENIYLLNLAVSNLCFLLTLPFWAHAGGDPMCKILIG 1 2 0
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
NM_0 03 9 6 5  LYFVGLYSETFFNCLLTVQRYLVFLHKGNFFSARRRVPCGIITSVLAWVTAILATLPEFV 16 8
A F 0 1 5 5 2 4  LYFVGLYSETFFNCLLTVQRYLVFLHKGNFFSARRRVPCGIITSVLAWVTAILATLPEFV 1 8 0
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
NM_0 03 9 6 5  VYKPQMEDQKYKCAFS RTP FLPADETFWKHFLTLKMNISVLVLPLFIFTFLYVQMRKTLR 2 2 8
AFO1 5 5 2 4  VYKPQMEDQKYKCAFSRTPFLPADETFWKHFLTLKMNISVLVLPLFIFTFLYVQMRKTLR 2 4  0
-k-k'k'k'kic'k'k'k'k'k'kic'k'k'k'k-k'kic'k'k'k'k'k'kjc'k'k'k'k'k'k'k'k-k'kic'k'k'k'k'k'k'kiir'k'k'k'k'k'k-k-k-kic'k'k'kic
NM _003 9 6 5  FREQRYSLFKLVFAIMWFLLMWAPYNIAFFLSTFKEHFSLSDCKSSYNLDKSVHITKLI 2 8 8
AFO1 5 5 2 4  FREQRYSLFKLVFAVMWFLLMWAPYNIAFFLSTFKEHFSLSDCKSSYNLDKSVHITKLI 3 0 0
• k - k - k - k - k -k - k -k i c - k - k -k - k -k  • • k - k ' k - k - k ' k ' k - k - k - k ' k - k ' k ' k - k ' k - k ' k ' k ' k ' k ' k i r - k - k ' k ' k ' k ' k - k ' k - k - k ' k - k - k - k - k ' k ' k - k ' k - k - k - k
NM _003 9 6 5  ATTHCCINPLLYAFLDGTFSKYLCRCFHLRSNTPLQPRGQSAQGTSREEPDHSTEV 3 4 4
AFO1 5 5 2 4  ATTHCCINPLLYAFLDGTFSKYLCRCFHLRSNTPLQPRGQSAQGTSREEPDHSTEV 3 56
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Figure 4.1 ClustalW Protein sequence alignment of human CCRL2A (AF015524) 
with CCRL2B (NM_003965).
The alignment shows that the two proteins are identical, as indicated by asterisks, 
differing only in their N-terminal part. The following symbols denote the degree of 
conservation observed in each column: means that the residues in that column are
identical in all sequences in the alignment. means that conserved substitutions have 
been observed. Red means small+ hydrophobic (incharomatic -Y) residues; blue means 
acidic residues; magenta means basic residues, green means hydroxyl + amine + basic -  
Q residues.
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Figure 4.2 Schematic representation of CCRL2 gene.
A Red colour represents sequence o f exons on chromosome 3p21 coding for CCRL2, 
yellow are alignment o f the two different mRNA sequences present in the databases and 
blue represent the protein sequence o f the two CCRL2 splicing variants. B Structure of 
cDNA encoding CCRL2A and CCRL2B. Thin lines represent non translated regions; 
dashed diagonal lines represent introns; thick lines represent coding regions. The 
drawing is not to scale.
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4.3.2 Cloning of CCRL2 A and B receptor variants and transfection in L1.2 and 
CHO-K1 cell line
CCRL2A and B were cloned from cDNA derived from LPS treated dendritic cells. 
Primers to amplify the full-length sequence for CCRL2 were chosen according the two 
sequences AFO 15524 and NM 003965 for CCRL2A and B respectively. The resulting 
PCR products were cloned into the BamWl - Not I sites o f pcDNA 3.1 and sequenced. 
The two plasmids were transfected with Lipofectamine 2000 in CHO-K1 cells 
according to the manufacturer’s instructions. After 24 hours cells were detached and 
studied with FACS analysis with a monoclonal antibody against CCRL2. As shown in 
Figure 4.3 nearly 20% of transfected cells expressed CCRL2 on their membrane. 
Similar transfection efficiency was obtained with CCRL2A (data not shown).
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Figure 4.3 FACS analysis of CCRL2B bulk transfection.
CHO cells after 24 hours from transfection with CCRL2B expression plasmid were 
subjected to FACS analysis for CCRL2 expression by the use of specific monoclonal 
antibodies. Each panel contains the percentage o f positive cells and the mean 
fluorescence intensity of CCRL2 expression.
114
Chapter 4. Generation of CCRL2 transfectants and screening for CCRL2 agonists
Cells were then selected with G418 at a concentration of 500ug/ml for approximately 2 
weeks in order to produce stable transfectants. Single cell cloning was performed using 
limiting dilution technique and the resulting cell clones were checked by RT-PCR for 
CCRL2 mRNA expression. Mock transfections were performed with empty vector. 
Figure 4.4 shows RT-PCR of 10 CHO clones obtained from CCRL2B transfection. 
Clones G7 as negative and clones D7, G10 and H6 that express high levels of CCRL2B 
mRNA were further subjected to FACS analysis in order to check protein expression. 
As expected the negative clone G7 did not express CCRL2 protein while two out of 
three CCRL2B mRNA positive clones (G10 and H6) showed high level of CCRL2 
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CCRL2
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Figure 4.4 Expression of CCRL2B in CHO clones.
2pg of total RNA was used in RT-PCR experiments using specific primers for CCRL2B 
and b-actin. Number of cycles for CCRL2B and P-actin were 32 and 28 respectively 
Ethidium bromide staining for both genes is shown.
115
Chapter 4. Generation o f CCRL2 transfectants and screening for CCRL2 agonists
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Figure 4.5 FACS analysis of CCRL2B expressing clones.
CCRL2B/CHO transfectants were subjected to FACS analysis for CCRL2 expression 
by the use o f specific monoclonal antibodies. Each panel contains the percentage of 
positive cells and the mean fluorescence intensity of CCRL2 expression. Results are 
representative of two separate experiments.
Due to the correlation between mRNA and protein data we proceeded with the 
screening of other clones o f both CCRL2A and B using only FACS analysis as shown 
in Figure 4.6.
From CCRL2B cloning we obtained six clones and only three o f them were positive 
with weak immunoreactivity, indicative of low surface expression o f the receptor 
(Figure 4.6A), while we were able to obtain more clones with higher levels o f receptor 
expression from CCRL2A transfection (Figure 4.6B).
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Figure 4.6 Screening of CCRL2A and B/CHO clones.
CCRL2A and B/CHO transfectants were subjected to FACS analysis for CCRL2 
expression by the use of specific monoclonal antibodies. Orange histograms represent 
negative control, green histogram represent CCRL2 staining. Each panel contains the 
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In order to maximize expression of the vector-expressed CCRL2 we treated cells with 
sodium butyrate, an inhibitor of histone deacetylases (HDACs) that induces gene 
expression. In fact acetylation correlates with nucleosome remodeling and 
transcriptional activation while deacetylation of histone tails induces transcriptional 
repression through chromatin condensation. Relaxation of the chromatin structure 
induced by HDACs facilitates the accessibility of a variety of factors to DNA (244).
We focused our attention on three clones of CCRL2A/CHO (D2, E7, E8) and on three 
clones of CCRL2B/CHO (A6, C5, BIO) measuring membrane protein levels by FACS 
analysis before and after treatment with sodium butyrate over night. Figure 4.7 shows 
that there was at least 3-fold increase in cell surface CCRL2 in all clones following 
butyrate treatment, indicating that this is the best condition to use for our screening 
analysis.
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Figure 4.7 Effect of sodium butyrate treatment on CCRL2A and B/CHO clones.
CCRL2A and B/CHO transfectants were cultured at different concentrations in the 
absence or presence o f sodium butyrate and then subjected to FACS analysis for 
CCRL2 expression by the use of specific monoclonal antibodies. Orange histograms 
represent negative control. Each panel contains the mean fluorescence intensity o f 
CCRL2 expression.
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During our analysis we noticed that CCRL2 expression in clones was not stable. For 
example CCRL2B expression in clone BIO had a MFI of 14.71 in the experiment shown 
in fig 4.6A that was reduced at 5.71 in the experiment shown in fig.4.7. The same 
problem was noticed for CCRL2A levels: for example CCRL2A expression of clone E8 
that was MFI=25.13 in figure 4.6 and MFI=4.2 in figure 4.7.
In order to identify the best conditions in which the transgene was expressed we 
cultured cells at different concentrations. So cells were plated at different densities 
(20.000, 100.000 and 500.000 cells/well) and the day after detached and stained for 
CCRL2 expression. As shown in Figure 4.8 there was a 3-fold increase in cell surface 
CCRL2A and B levels when cells were plated at lower density (20.000 cells/well) in 
comparison with cells cultured at higher density (500.000), suggesting a correlation 
between plasmid expression and cell cycle or cell confluence. This behaviour was 
present also when cell were pre-treated with sodium butyrate (Figure 4.8), even if the 
difference is lower being nearly 2 fold. There are reports that correlate chemokine 
receptor expression with cell cycle phases (245) and it is possible that expression of 
CCRL2 is higher when cell are duplicating and is downregulated when cells arrest their 
cycle after reaching confluence.
The mouse LI.2 lymphoma cell line was transfected by electroporation with linearized 
vectors and selected with 800 pg/ml G418; resistant cells were cloned by limiting 
dilution. Screening of positive clones was done using the same approach shown before 
for CHO transfectants (data not shown).
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Figure 4.8 CCRL2 expression in CHO transfectants cultured at different 
concentrations.
CCRL2A and B/CHO transfectants were cultured at different concentrations in the 
absence or presence o f sodium butyrate A FACS analysis for CCRL2 expression by the 
use of specific monoclonal antibodies. Orange histograms represent negative control, 
green histograms 20.000 cells/well, pink 100.000 cells/well and blue 500.000 cells/well. 
B CCRL2 mean fluorescence intensity o f the same FACS analysis.
4.3.3 Chemotaxis and Calcium flux
L I.2 cells transfected with CCRL2A and CCRL2B were chosen to perform chemotaxis 
and calcium flux experiments because they represent a very useful cell model for this 
functional assay. Cells were treated overnight with sodium butyrate in order to 
maximize CCRL2 expression and cell migration was performed with Transwell system 
with a broad panel o f human chemokines. Figure 4.9 shows that CCRL2B/L1.2 were 
not able to migrate in response to all chemokine tested: CCL1, CCL2, CCL3, CCL4, 
CCL5, CCL7, CCL11, CCL13, CCL15, CCL17, CCL18, CCL19, CCL20, CCL21, 
CCL22, CCL25, CXCL8 and CXCL10. As expected, cells were able to migrate in 
response to CXCL12, the ligand of the endogenous receptor CXCR4. Moreover 
transfectants did not migrate in response to supernatants obtained from different tumor
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cell lines (data not shown). Similar results were obtained with CCRL2A/L1.2 cells (data 
not shown).
Another consequence of chemokine receptor stimulation is the activation of G-protein- 
sensitive PLC isoforms, resulting in the generation of DAG and inositol 3,4,5- 
triphosphate, which leads to the release of Ca2+ from intracellular stores. Hence, we 
analyzed chemokine-induced Ca2+ mobilization in CCRL2A and B transfectants. 
CCRL2B/L1.2 did not flux in response to all chemokines tested (CCL4, CCL3, CCL1, 
CCL2, CCL16, CCL15, CCL5 and CCL13 as shown in Figure 4.10). Moreover Ca2+ 
mobilization experiments were negative using other CC chemokines (CCL7, CCL11, 
CCL17, CCL18, CCL19, CCL22, CCL25; data not shown). As shown in Figure 4.10 
CCRL2B transfectants exhibited a small flux in response to CCL2 and CCL5 that were 
due to endogenously expressed murine CCR2 and CCR5 (246, 247). In fact the same 
calcium fluxes were detectable in untransfected cells (data not shown). As shown in 
Figure 4.10A, CXCL12 was able to induce a strong calcium flux due to the endogenous 
murine CXCR4 expression.
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Figure 4.9 Chemotaxis assays with L1.2 cells stably transfected with CCRL2B.
Cells were stimulated in separate experiments with the different chemokines at the 
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Figure 4.10 Intracellular calcium measurements in L1.2 cells stably transfected 
with CCRL2B.
Cells were stimulated with lOOnM recombinant human CCL4, CCL3, CCL1, CCL2, 
CCL16 and CXCL12 (A) and with CCL15, CCL5 and CCL13 (B). The arrows indicate 
the moment of stimulus. The experiments were repeated at least 2 times. Note the 
different scale o f y axis.
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4.4 Discussion
Alternative splicing produces two CCRL2 mRNA variants, predicted to encode two 
different receptors CCRL2A and CCRL2B. CCRL2A is predicted to contain 12 
additional amino acids at its N terminus as compared with CCRL2B. Alternative 
splicing is well described as a mechanism of generating diversity among G protein- 
coupled receptors, resulting in changes in the C termini and intracellular loops as well as 
truncated receptors, sometimes resulting in changes in receptor activities (reviewed in 
Ref. (248)).Although the coding regions of chemokine receptor genes are often found on 
single exons, there are now examples of exceptions to this rule, including, the genes for 
CCR2 (249) and mCXCR4 (250). Alternative splicing produces two forms of human 
CCR2, CCR2A and CCR2B, which differ in their C-terminal regions (249), and two 
forms of mouse CXCR4, which differ by 2 aa within the N-terminal region (250).
With regard to activities for chemokine receptor variants arising from alternative 
splicing, functional studies have revealed differences in the responses to ligands 
between the two forms of CCR9 (243). The splicing that gives origin to the two forms 
of CCR9, CCR9A and CCR9B, is identical to that of CCRL2. Functional studies have 
revealed that CCR9A is the more efficient receptor in terms of calcium fluxes, 
chemotaxis and binding affinity
Starting from this observation, in order to identify potential ligands we cloned both 
receptor variants. CCRL2A and B were cloned and expressed in CHO and LI.2 cell 
lines and stable clones were generated. In order to maximize CCRL2 expression cells 
were treated overnight with the histones deacetylases inhibitor sodium butyrate, 
probably because this treatment caused relaxation of the chromatin structure facilitating 
the accessibility of a variety of factors to DNA (244). Moreover cells had to be cultured 
at low densities conditions because we observed a decrease of 3-fold in basal conditions
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and of 2-fold after sodium butyrate treatment of CCRL2 surface expression after 
reaching confluence. This observation may suggest that CCRL2 expression is related to 
cell cycle. It was published that in primary cultures of human micro vascular endothelial 
cells (HMVECs) CXCR3 expression is limited to the S/G2-M phase of their cell cycle 
(245) and that CXCR3 agonists block HMVEC proliferation explaining angiostatic 
effect of these molecules. So it will be interesting to study in primary cells if CCRL2 
expression is related to cell cycle.
Having found the best conditions to use in order to maximize CCRL2 expression we 
performed screening assays using LI.2 transfectants. Chemotaxis and calcium flux 
experiments suggested that both CCRL2 splicing variants were not able to respond to 
most CC chemokines (fig 4.9). Our data are in contrast with previously published paper 
of Biber et al (142) that demonstrated that the murine homolog of CCRL2, named 
LCCR was a functional chemokine receptor for the chemokines CCL2, CCL5, CCL7, 
and CCL8, although the authors did not show evidence for a direct ligand-receptor 
interaction such as radioligand binding.
We are not able to explain such differences, our experiments were performed with a 
different cell line, LI.2, while Biber group used HEK293 cells. LI.2 is a mouse pre-B 
cell line frequently used to express chemokine receptors (251-253) because chemotaxis 
and calcium flux assays are easy to perform. Moreover this cell line expresses 
endogenously high level of CXCR4 used as positive control. We cannot exclude that 
this cell line does not contain the right G protein to transduce a signal different from 
chemotaxis after CCRL2 engagement, although Yoshimura et al. (139) describe that 
cells expressing either CCRL2 splice variants migrated in response to a fraction of 
rheumatoid arthritis synovial fluid, indicating that CCRL2 is a functional receptor.
Taken together our results do not address the question whether CCRL2 is a signalling 
receptor.
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Conclusions from this chapter:
• CCRL2 exists in two spicing variants, CCRL2A and B, that differ for their N 
terminal domain
• Transfectants for both splicing variants express the receptor on membrane
• Levels of CCRL2A and B expression positively correlate with low density 
conditions of culture
• CCRL2A and B/L1.2 transfectants do not migrate or calcium flux in response 
to a broad panel of CC chemokines
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5 Chapter 5. Comparison of CCRL2 and D6: is 
CCRL2 a second chemokine scavenger receptor?
5.1 Introduction
Although there are numerous examples of the identification of ligands for orphan 
GPCRs, there has been a decrease in the number of published orphan receptor/ligand 
pairings in the past two years. This suggests that traditional approaches for the 
identification of ligands for orphan GPCRs, largely based on the screening of putative 
GPCR ligands, will not be successful for the identification of ligands of the remaining 
160 or so orphan GPCRs and alternative approaches are required. Indeed, this also 
raises the possibility that not all orphan GPCRs require a ligand, and some may play an 
alternative role in cell biology (241).
Referring to chemokine receptors, beside “classic” conventional signalling receptors, 
other chemokine binding molecules with high structural similarity to chemokine 
receptors have been described, namely the Duffy antigen receptor for chemokines 
(DARC) (112), D6 (106) and (105), and CCX CKR (123). In addition a chemoattractant 
receptor, C5L2, with similarity to C5aR andC3aR, has been cloned; it binds C5a and the 
desarginated forms of both C5a and C3a (102). These molecules are characterized by 
distinct patterns of tissue distribution and different ligand specificities, but they share 
the ability to bind chemokines with high affinity in the absence of any demonstrable 
signalling function, and therefore are now indicated as “silent” receptors. “Silent” 
receptors have been suggested to favour transfer of chemokines across endothelial 
barriers and/or to act as decoy receptors which dampen inflammatory reactions (95).
It is interesting to note that all “silent” chemokine receptors present alterations in the 
DRYLAR/IV motif in the second intracellular loop, which is critical for G protein
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coupling and signalling functions in conventional receptors, and maybe such alteration 
may represent a first hallmark of decoy receptors. The analysis of the CCRL2 amino 
acid sequence reveals the presence of two main alterations: a substitution of a highly 
conserved aspartic acid residue to asparagine, in the second transmembrane domain 
(N82), a residue present in almost all seven transmembrane receptors (58). Moreover 
CCRL2 has an alteration of the sequence in the DRYLAIV motif of the third 
intracellular loop (QRYLVFL). Because of sequence similarities between CCRL2 and 
silent or decoy chemokine receptors, we decided to perform internalisation assays in 
both CHO-CCRL2 and CHO-D6 transfectants.
5.2 Aim of the chapter
This chapter investigated the ability of CCRL2 transfectants to scavenge CC 
chemokines. The screening was performed in parallel with D6 transfectants and allowed 
the identification of new ligands for this receptor. Subsequently internalization of both 
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5.3 Results
5.3.1 Analysis of CCRL2-dependent chemokine scavenging: comparison with D6
CCRL2B and D6/CHO-K1 transfectants were incubated for 3 h with 1.2 nM of various 
chemokines. At the end of the incubation, the chemokine concentration in the 
supernatant was measured by ELISA. As shown in Figure 5.1, no chemokine was 
scavenged by CCRL2B while among known D6 ligands, the inflammatory CC 
chemokines CCL5, CCL11 and CCL22, were scavenged with the highest efficiency 
(94.3 ± 0.2%, 92.5 ± 2.1% and 91.99+ 1.2% of the initially seeded chemokine, 
respectively). CCL7, CCL4, CCL2, CCL3L1 and CCL17 were scavenged with 
intermediate efficiency (85.1 ± 0.5%, 83.9 ± 2.9%, 76.5 ± 2.2%, 76.0 ± 6.6% and 
61.2±11.9% of the initially seeded chemokine, respectively). Interestingly, CCL3 and 
CCL3L1, which only differ for the presence of a serine or a proline residue in position 
2, were scavenged with different efficacy (29.0 ±4.1% and 76.0 ± 6.6% of the initially 
seeded chemokine, respectively), in agreement with previous results reporting that only 
the CCL3L1 variant is a high affinity D6 ligand (254). CCL1, which does not bind D6 
(105), was the only inflammatory CC chemokine tested not scavenged by D6 (3.1 ± 
1.4% of the initially seeded chemokine). None of the chemokines tested was scavenged 
by untransfected CHO-K1 cells. Unlike CC inflammatory chemokines, the homeostatic 
chemokines CCL19 and CCL20, agonists at CCR7 and CCR6 respectively, were not 
scavenged (8.2 ± 9.2% and 6.7 ± 12.5% of the initially seeded chemokine, respectively). 
As expected (105), the CXC chemokine CXCL8 was not scavenged by D6 transfectants 
(2.4 ± 7.3% of the initially seeded chemokine).
Thus, D6 scavenges with variable efficacy agonists of the inflammatory chemokine 
receptors CCR1 (CCL3, CCL3L1, CCL5, and CCL7), CCR2 (CCL2 and CCL7), CCR3
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(CCL5 and CCL11), CCR4 (CCL17 and CCL22) and CCR5 (CCL3, CCL3L1, CCL4 
and CCL5).
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Figure 5.1 CCRL2B and D6-mediated chemokine scavenging.
Untransfected CHO-K1 cells (white bars) or CCRL2B/CHO-K1 cells (black bars) or 
D6/CHO-K1 cells (gray bars) were incubated for 3 h with 1.2 nM o f different 
chemokines. At the end of the incubation, the chemokine concentration in the 
supernatants was measured by ELISA. Results are expressed as % o f scavenged 
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5.3.2 Identification of new D6 ligands
Among inflammatory chemokines, the CCR4 agonists CCL22 and CCL17 were not 
previously investigated for their ability to interact with D6 (105). As shown in Figure 
5.1, both chemokines were efficiently scavenged by D6. Figure 5.2 shows that CCL17 
was less efficiently removed than CCL22 by D6/CHO-K1 transfectants at short time 
points (69.7 ± 3.0 % and 86.4 ± 1.3% of the initially seeded chemokine at 1 h for 
CCL17 and CCL22, respectively), while at longer times of incubation, the two CCR4 
agonists were scavenged with comparable efficacy (81.8 ± 2.6 % and 89.6 ± 2.6% of the 
initially seeded chemokine at 6 h, respectively). CCL17 and CCL22 scavenging was 
also analyzed in D6/L1.2 and D6/MELC-2 transfectants, with similar results (data not 
shown).
Since ELISA may detect partially degraded forms of chemokines, we tested the 
effective biological inactivation of CCL22 by analyzing the chemotactic activity of 
CCL22 preincubated with untransfected CHO-K1 or D6/CHO-K1 transfectants on 
CCR4/L1.2 transfectants (Figure 5.3A). After 3 h preincubation with untransfected 
CHO-K1 cells, the chemotactic activity of CCL22 was unaffected, whereas incubation 
with D6/CHO-K1 transfectants drastically reduced (> 100 times) the CCL22-mediated 
chemotactic activity, in agreement with ELISA results.
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Figure 5.2 Kinetics of D6-mediated CCL17 and CCL22 scavenging
D6/CHO-K1 cells were incubated with 1.2 nM of CCL17 (•) or CCL22 (o) at 37°C for 
the indicated periods. At the end of the incubation, the chemokine concentration in the 
supernatants was measured by ELISA. Results are expressed as % of scavenged 
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Figure 5.3 D6-mediated inactivation of CCL22 chemotactic activity
(A) Migration of CCR4/L1.2 cells in response to increasing concentrations of CCL22 
(•) or CCL22 preincubated with parental CHO-K1 (□) or D6/CHO-K1 cells (■). *, p < 
0.05; **, p < 0.01, compared to CCL22 activity after preincubation with untransfected 
cells. (B) Migration of CCR4/L1.2 (□) and CCR4-D6/L1.2 cells (■) in response to 
increasing concentrations of CCL22. Figures show a representative experiment of three 
performed with similar results. Values are the number of migrated cells (mean ± SD). 
**, p < 0.01 compared to CCR4/L1.2 cells.
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In order to define the functional outcome of coexpression of CCR4 and D6 in the same 
cell context, LI.2 transfectants stably co-expressing both CCR4 and D6 (CCR4- 
D6/L1.2) have been generated. Flow cytometry analysis showed comparable expression 
of the two receptors (data not shown). When tested in chemotaxis assay, CCR4-D6/L1.2 
cells completely lost ability to migrate in response to CCL22 (Figure 5.3B). On the 
contrary, cell migration in response to CXCL12, a chemokine not scavenged by D6 
acting on the endogenous CXCR4, was unaffected by D6 coexpression (data not 
shown).
The interaction of CCR4 agonists with D6 was further investigated on D6/L1.2 
transfectants in competition binding experiments with 125I-CCL2 (Figure 5.4). D6 binds 
CCL22 more strongly (Ki = 0.33 nM), similarly to CCL2, while it binds CCL17 more
I OC
weakly (Ki = 2.9 nM), similarly to CCL4. Similar results were obtained using I- 
CCL22 (data not shown). As expected, CCL19 did not bind to D6. Since for some G- 
protein-coupled receptors the apparent affinity of ligands can vary depending on the
1 o r
tracer, competition binding experiments have also been performed using I-CCL4, 
with similar results (data not shown).
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Figure 5.4 Binding of CCL17 and CCL22 to D6
Competitive binding of 125I-CCL2 (mean ± SD) to D6/L1.2 cells in the presence of 
different concentrations of unlabelled CCL2 (■), CCL4 (♦), CCL17 (A), CCL19 (*) or 
CCL22 (•). Binding to untransfected LI.2 cells was 320±59 cpm/sample. The figure 
shows a representative experiment of at least three performed with similar results.
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As for other D6 ligands, treatment of D6/L1.2 transfectants with either CCL17 and 




















Figure 5.5 CCL17 and CCL22 chemotactic activity on CCR4 and D6 transfectants
Migration of CCR4/L1.2 (closed symbols) and D6/L1.2 (open symbols) in response to 
increasing concentrations of CCL17 (square) and CCL22 (circle). The figure shows a 
representative experiment of at least three performed with similar results. Values are the 
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CCL22 is processed by the dipeptidyl-peptidase IV (CD26) to produce the truncated 
forms CCL22 (3-69) and CCL22 (5-69), that lack, respectively, the first two and four 
amino acids at the NH2 terminus and lose their agonist activity on CCR4 transfectants 
(255, 256). It was important to assess whether the promiscuous CC chemokine D6 
receptor was able to interact with processed CCL22. As shown in Figure 5.6A, after 
three hours of incubation, D6 expressing cells scavenged unprocessed CCL22 (94.6 ± 
1.8% of the initially seeded chemokine), but not the processed variants CCL22 (3-69) 
and CCL22 (5-69) (1.3 ± 3.6% and 3.5 ± 12.0% of the initially seeded chemokines, 
respectively). In order to understand whether the lack of scavenging of the NH2- 
truncated molecules was due to their lost ability to interact with D6, competition 
binding analysis on D6/L1.2 transfectants using 125I-CCL2 as tracer were performed. As 
shown in Figure 5.6B, CCL22 (3-69) and CCL22 (5-69), unlike native CCL22, were 
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Figure 5.6 Differential binding and scavenging of native and truncated CCL22 by 
D6.
(A) D6-mediated scavenging of CCL22, CCL22 (3-69) and CCL22 (5-69). 
Untransfected (white bars) or D6-transfected CHO-K1 cells (black bars) were incubated 
for 3 h with 1.2 nM of CCL22, CCL22 (3-69) or CCL22 (5-69). Results (mean ± SD) 
are the percentage o f scavenged chemokine as assessed by ELISA. The figure shows a 
representative experiment o f at least three performed with similar results. **, p < 0.01 
compared to CCL22 scavenging. (B) Competitive binding of 125I-CCL2 (mean ± SD) to 
D6/L1.2 cells in the presence of different concentrations o f unlabelled CCL2 (■), 
CCL22 (•) , CCL22 (3-69) ( A)  or CCL22 (5-69) (*). The figure shows a representative 
experiment of at least three performed with similar results.
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5.3.3 Analysis of CCRL2 internalization: comparison with constitutive and 
ligand independent internalization of D6
To determine whether ligand binding would induce D6 internalization, D6/L1.2 and 
CCR4/L1.2 cells were labelled with the appropriate receptor-specific monoclonal 
antibody at 4°C, incubated at 37°C in the presence or absence of the ligand (60 nM 
CCL22) for indicated time periods, and labelled with appropriate secondary antibody. 
Receptor expression levels were analyzed by flow cytometry as described in methods. 
As shown in Figure 5.7, CCL22 induced a significant and rapid decrease of cell surface 
CCR4 expression levels, in agreement with previous reports (257). On the contrary, a 
significant fraction of D6 receptors underwent internalization both in the presence and 
in the absence of the ligand, and the treatment with the ligand (60 nM CCL22) was 
unable to induce any further receptor internalization. Similar results were obtained using 
an anti-HA monoclonal antibody, recognizing an HA tag inserted at the N-terminus of 
D6 and CCR4 (data not shown).
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Figure 5.7 D6 and CCR4 internalization
D6 internalization. D6/L1.2 (square) and CCR4/L1.2 (circles) cells were firstly labelled 
with primary antibody at 4°C for lh  and then incubated in medium (open symbols) or 
medium containing 60 nM CCL22 (closed symbols) for the indicated time periods at 
37°C. Cells were cooled on ice, washed with cold medium, and then labelled with 
secondary antibody at 4°C to determine the cell surface receptor levels. *, p < 0.05; **, 
p < 0.01 compared to CCR4/L1.2 cells incubated with medium alone.
GPCR recycling may be determined by measuring surface reappearance at various times
after inducing internalization by agonist. To determine D6 surface expression following
internalization, D6/L1.2 cells were labeled with anti-D6 monoclonal antibodies either
only before or before and after incubation at 37 °C for the indicated time periods, and
the surface expression o f D6 was analyzed. As above, cells stained only before
incubation displayed a significant rate o f receptor internalization (Figure 5.8). Labeling
of the cells with anti-D6 monoclonal antibodies after the internalization step revealed
that a significant fraction of internalized receptors was replaced on the cell membrane.
Taken together, these results indicate thatD 6 behaves as a constitutively active receptor,
undergoing rapid and ligand-independent internalization and re-expression on
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membrane. Similar experiments were performed with CCRL2A and B transfectants, in 
order to understand if also these receptors are constitutively internalized. As shown in 
Figure 5.8 CCRL2B trasfectants, differently from D6 did not undergo significant 
internalization and similar stainings were obtained labeling cells with anti-CCRL2 
monoclonal antibodies either only before or before and after incubation at 37 °C
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Figure 5.8 CCRL2 and D6 internalization
D6/L1.2 and CCRL2B cells were stained with anti-D6 or anti-CCRL2 primary antibody 
and incubated at 37 °C for 1 hour. After transfer at 4 °C, cells were stained again 
(restaining) or not with the primary antibody and then with the secondary antibody. The 
symbols are as follows: anti-D6, no restaining (o), anti-D6, restaining (•) , anti-CCRL2, 
no restaining (□), anti-CCRL2 restaining (■). Data are representative o f at least three 
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5.3.4 Cloning and characterization of murine D6
Previous studies reporting lack of signaling and decoy activity of D6 were focused on 
the human molecule (105) (108). It was therefore important to assess whether mouse D6 
shares these key properties with its human orthologue. For this reason murine D6 was 
cloned in pcDNA3 expression vector and then expressed in LI.2 and CHO cell lines. 
Similarly to the human counterpart, mouse D6 behaves as a silent receptor, in terms of 
calcium fluxes and chemotaxis (Figure 5.9A, and data not shown), and as a 
promiscuous, efficient scavenger of inflammatory CC chemokines with the expected 
ligand selectivity (Figure 5.9B).
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Figure 5.9 Functional analysis of murine D6.
(A) Chemotactic activity. Migration o f mD6/L1.2 (open symbols) and mCCR2/L1.2 
(closed symbols) transfectants in response to CCL2 (circles) and to the homeostatic 
chemokine CXCL12 (squares), which is not recognized by D6 but acts via the 
endogenously expressed receptor CXCR4, was evaluated on 5-pm pore-size Transwell 
fdters (Corning, New York, USA). Migrated cells were counted on a Burker chamber. 
Results are means±SD of triplicate samples o f one experiment that is representative o f 
three performed. (B) Chemokine scavenging. Either mD6/CHO-Kl (open bars) or 
untransfected CHO-K1 (closed bars) cells were incubated at 37°C for 5h with the 
indicated chemokines. Results are means±SD of triplicate samples o f one experiment 
that is representative o f three performed.
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5.4 Discussion
Results presented here indicate that both CCRL2 variants were not able to 
internalize/scavenge a broad panel of CC chemokines. In contrast, the same screening 
analysis on D6 transfectants confirmed and extended previous observations on the 
promiscuous binding (105) and scavenging (108) of CC chemokines by this receptor. 
Although chemokine classification in homeostatic and inflammatory is not absolute 
(258, 259), it was found that D6 only recognizes and scavenges inflammatory 
chemokines, including CCR1 through CCR5 agonists.
Conversely D6 did not interact with CC chemokines such as CCL19 (CCR7 ligand) and 
CCL20 (CCR6 ligand), usually behaving as homeostatic chemokines. Thus, the 
spectrum of ligands recognized by D6 contrasts with that of CCX-CKR, which binds 
the homeostatic chemokines CCL19, CCL21 and CCL25 but not inflammatory 
chemokines (123). It is at the moment unclear whether CCX-CKR internalizes and 
scavenges homeostatic CC chemokines, as D6 does for the inflammatory ones (226).
In addition to already known ligands, the results presented here indicate that the 
spectrum of chemokines recognized by D6 also includes the CCR4 agonists CCL22 and 
CCL17. CCL22 and CCL17 are constitutively expressed in lymphoid organs, in 
particular in the thymus, spleen, lymph nodes and to a lesser extent in the gut (260). 
Immature myeloid DC constitutively express low levels of CCL22 (261). However, as 
inducible chemokines, CCL22 and CCL17 are part of regulatory circuits of polarized 
Thl and Th2 responses. IL-4 and IL-13 induce CCL22 production, whereas IFN-y 
inhibits it (185). Moreover, inflammatory signals (e.g. LPS) augment CCL22 
production (262, 263). Hence, CCL22 and CCL17 belong to both realms of homeostatic 
and inflammatory chemokines, and their recognition by D6 is therefore consistent with 
the general preferential interaction of this decoy receptor with inflammatory proteins.
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DC express CCR4 and respond to CCR4 agonists. CCL22 has been suggested to play a 
role in the trafficking of epidermal Langerhans cells at the inflammatory site (264) and 
in the formation of T cell-DC clusters in both inflamed skin and lymph nodes (265, 
266). D6 is strategically located on endothelial cells lining afferent lymphatics (107) 
and has been suggested to act as a gatekeeper to prevent excessive transfer of 
inflammatory chemokines to lymph nodes. By recognizing CCR4 agonists, D6 may 
regulate DC migration to lymph nodes via afferent lymphatics.
CCL22 is processed by dipeptidyl peptidase IV (CD26) to produce the processed 
variants CCL22 (3-69) and (5-69), which loose the capacity to interact with CCR4 (255, 
256). Dipeptidyl peptidase IV is widely expressed in cells and tissues and is more 
abundant in Thl compared to Th2 cells (255, 260). Interestingly, processed CCL22 
forms are not recognized by the promiscuous receptor D6. The selective recognition of 
CCL22 versus CCL22 (3-69) and CCL22 (5-69) may represent a strategy to focus the 
decoy function on the CCR4 agonists, without interference from inactive processed 
forms.
Results presented here also demonstrated that the chemokine receptor D6, differently 
from CCR4, is constitutively internalized in a ligand independent way. Ligand binding 
of a typical GPCR results in a series of events including G-protein activation, receptor 
phosphorylation, desensitization, b-arrestin association, sequestration, and/or 
internalization. D6 might be in a constitutively active conformation but unable to 
transduce G-protein-mediated signals due to specific mutations in regions of the 
receptor essential for G-protein as an asparagine in place of an aspartic acid in the 
second transmembrane domain and a change in the canonical DRYLAIV motif in the 
second cytoplasmic loop to DKYLEIV in D6. Both regions were shown to be important 
in G protein-dependent signaling in chemokine receptors (95). It is also possible that
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multiple mutations may have occurred to generate D6 as a non-signaling receptor. 
Indeed, two other chemokine receptors, US28, a cytomegalovirus-encoded chemokine 
receptor with broad ligand specificity (103), which has also been proposed as a 
chemokine scavenger receptor, and a constitutively active mutant of CXCR4 (CXCR4- 
CAM) are known to undergo constitutive internalization (267, 268). However, unlike 
D6, these receptors transduce G-protein-mediated signals. A second possible 
mechanism is that the cytoplasmic tail of D6 contained a structural element allowing it 
to constitutively internalise.
Analysis of CCRL2 internalization with antibody feeding experiments, showed very 
little if any, constitutive internalization of this receptor (Figure 5.9). Collectively from 
results presented in this chapter we can conclude that CCRL2, despite structural 
similarities with chemokine silent or decoy receptors, does not scavenge any CC 
chemokine tested and does not constitutively internalise in a ligand-independent way.
Conclusions from this chapter:
• CCRL2 does not mediate CC chemokine scavenging
• D6 scavenges CC chemokines that bind receptors from CCR1 to CCR5
• D6 mediates inactivation of CCL17 and CCL22 chemotactic activity
• CCL17 and CCL22 bind D6 with high affinity but do not induce chemotactic 
activity
• Native and truncated CCL22 are differentially bound and scavenged by D6
• D6 but not CCRL2 is constitutively internalised in a ligand independent way 
and rapidly replaced on cell surface
147
Chapter 6-Summary and future plans
6 Chapter 6 Summary and future plans
6.1 Summary
6.1.1 The elusive orphan receptor CCRL2
Chemokines and their receptors have important roles in directing leukocyte traffic but 
also in several other functions from haematopoiesis to cancer metastasis. In 1998 Fan et 
al. (134) cloned an orphan seven transmembrane receptor with high homology and 
several characteristics common to chemokine receptors, such as peptide length, 
positioning of 4 extracellular cysteines and genomic localization in a chemokine 
receptor cluster.
For all these reasons we thought it important to try to deorphanize it. First we studied 
the sites of the orphan GPCR expression as a primary indication of its biological role. In 
human tissues CCRL2 is expressed at high levels in lung and lymphoid tissues. Among 
leukocytes CCRL2 is expressed mainly by cells of the myelomonocytic lineage, PMN 
and monocytes. Immature monocyte-derived DC express low levels of CCRL2 but 
maturative stimuli like LPS and CD40L strongly upregulated its expression in a 
transient way, with maximal expression at 2 hours and return to basal levels at 24h of 
stimulation. Another interesting aspect of CCRL2 expression in maturing DC is the 
downregulation by PGE2, an arachidonic acid metabolite that promotes the migration of 
mature human monocyte-derived DC to the CCR7 ligands CCL19 and CCL21. Several 
aspect of DC migration are still not clear, in particular which molecules determine DC 
entry to lymphatic vessels. Being CCRL2 expressed by maturing DC and regulated by 
PGE2 is likely to be involved in this process.
In order to identify CCRL2 ligands we have tried different approaches. CCRL2 exists in 
two splicing variants differing for the presence of 12 aminoacid in the N terminal 
region. Because this part of the receptor plays an important function in ligand binding
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we decided to clone and transfect both variants. First we performed functional assays as 
chemotaxis and calcium fluxes focusing our attention on CC chemokines because 
phylogenetic analysis strongly suggests that the CCRL2 putative ligand might be a 
chemokine of this family, but our effort was unsuccessful.
CCRL2 displays some characteristics typical of chemokine decoy receptors like a 
variation of the DRYLAIV motif in the second intracellular loop and an N/D 
substitution in the second transmembrane domain. Following the hypothesis that 
CCRL2 might be a decoy or silent chemokine decoy receptor we performed scavenging 
experiments with most of the CC chemokines but again unsuccessfully.
Finally we tried to understand if CCRL2 is constitutively internalized, a characteristic 
shared by chemokine decoy receptors. In contrast to D6 that is constitutively 
internalized in absence of ligands, CCRL2 is expressed on the cell membrane and is not 
internalized.
The expression profile of CCRL2 suggests that this receptor might have an important 
role in DC biology in particular in the migration from the periphery to lymph nodes. 
Despite the use of different approaches we have not been able to find a ligand for this 
receptor. We can assume that both CCRL2 variants, despite structural homologies with 
CC-receptors, are not able to induce migration and calcium fluxes to all CC chemokines 
tested. Moreover our analysis suggests that although CCRL2 shares structural 
characteristics with chemokine decoy receptors, it does not behave like a member of this 
family in terms of chemokine scavenging and constitutive internalization.
6.1.2 The inflammatory chemokine decoy receptor D6
We have identified two new ligands for D6 that are the CCR4 agonists CCL22 and 
CCL17. These chemokines are not able to induce migration of D6 expressing cells, but 
are rapidly scavenged by D6 and double transfectants CCR4/D6 lose the ability to
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migrate to both chemokines. Moreover we have found that D6 is not able to bind and 
scavenge both truncated versions of CCL22 named CCL22 (3-69) and CCL22 (5-69). 
These two proteins do not interact with CCR4 and have lost their ability to induce 
recruitment of Th2 cells. So our data suggest that D6 is able to scavenge inflammatory 
chemokine ligands from CCR1 to CCR5 but is a blind receptor not scavenging inactive 
forms of truncated chemokines.
Further work was done on the ability of D6 to constitutively internalize. D6 membrane 
levels, differently from CCR4, do not decrease following chemokine stimulation 
because the receptor is constitutively cycling in a ligand-independent manner. This 
behaviour is similar to that previously described for the human CMV-encoded 
chemokine receptor US28, which has also been proposed as a chemokine scavenger 
receptor.
6.2 Future plans
There are a number of questions arising from this thesis that should be answered by 
further work. The following sections will outline some of these issues.
6.2.1 Does CCRL2 form heterodimers with other chemokine receptors?
One hypothesis not investigated about the role of CCRL2 in chemokine biology is
heterodimerization. There is now extensive literature describing the phenomena of
GPCR dimerization (61). A number of techniques have been developed to demonstrate
that GPCRs are capable of forming both heterodimers and homodimers. The functional
relevance of this remains unclear and is the subject of intense speculation. It may be that
GPCR heterodimers or homodimers are required for the processing or trafficking of the
receptor. A well-characterized example of this is the GABA-B-R2 receptor, which
appears to function as a trafficking protein to deliver the functional GABA-B-R1
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receptor to the cell surface (269). The prominent current hypothesis is indeed that 
GPCRs assemble as dimers shortly after synthesis in the endoplasmic reticulum, and 
traffic as such throughout their life in the cell.
Chemokine receptors make no exception to this new rule and both homo- and 
heterodimerization were demonstrated for CC and CXC receptors. Oligomerization was 
reported for four chemokine receptors so far: CCR2, CCR5, CXCR2 and CXCR4 (61). 
Co-immunoprecipitation, BRET and FRET experiments have shown unambiguously 
that CCR2 and CCR5 are able to form both homo- and heterodimers. Functional 
analyses demonstrated negative binding cooperativity between the two subunits of a 
dimer. The consequence is that only one chemokine can bind with high affinity onto a 
receptor dimer.
In addition to their ability to form homodimers, or to associate with close structural 
relatives, chemokine receptors were also reported to form oligomers with receptors 
belonging to other families like AMPA glutamate receptors and opioid receptors but the 
exact molecular mechanisms and physiological consequences of cross-families 
dimerization events remain to be elucidated.
Although there is little published evidence for this, it remains possible that some orphan 
GPCRs may act as accessory proteins, which in combination with other orphan or 
liganded GPCRs, may modulate responses to known ligands or confer new ligand 
binding characteristics. This issue can be best addressed by taking a proteomics 
approach. CCRL2 could be epitope tagged, transfected into cell lines, and 
immunoprecipitation experiments to isolate receptor complexes performed. 
Alternatively, receptor combinations could be studied in mammalian cell lines using 
techniques such as bioluminescence resonance energy transfer (BRET) or time-resolved 
-fluorescence resonance energy transfer (TR-FRET).
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6.2.2 Does CCRL2 activate G-protein independent pathways?
It has been assumed that all signaling events mediated by GPCRs occur as a 
consequence of G-protein activation. As a consequence, all orphan GPCR ligand 
screening experiments have relied upon the detection of the ability of candidate ligands 
to activate one of the classical heterotrimeric G-protein signaling pathways. There are 
now a number of examples of GPCRs that activate signal transduction pathways 
through G-protein-dependent and -independent signaling pathways. Perhaps the first 
example of this phenomenon was the demonstration that in addition to classical G- 
protein-mediated signaling, the C-terminal tails of the p2-adrenoceptor and the P2Y1 
purinergic receptor interact with the Na+/H+ exchanger regulatory factor (NHERF) to 
directly regulate Na+/H+ exchange (270). Further examples of G-protein-independent 
signaling include the coupling of metabotropic glutamate receptors directly to 
intracellular calcium stores through homer proteins and GPCR activation of 
phospholipase D as a consequence of activation of the small G-proteins Arf and RhoA 
(271). This raises the possibility that there may be examples of the GPCR family that do 
not require G-proteins for signaling and that some of the remaining orphan GPCRs also 
signal through G-protein-independent mechanisms. If so, novel screening approaches 
will have to be established in order to identify activating ligands.
6.2.3 Role of D6 in DC migration
D6 expressed by lymphatic endothelial cells (LECs) might block the cellular responses 
to inflammatory chemokines and might enable the cells to leave tissues through 
receptors such as CCR7. This would facilitate the movement of antigen-presenting cells 
and lymphocytes from inflamed tissues to the draining LNs by desensitizing responses 
to inflammatory but not constitutive chemokines like CCL21 that promote lymphatic
entry of maturing DC that express CCR7 and preventing recruitment of immature DC.
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Moreover DC express the chemokine receptor CCR4 and respond to CCR4 agonists. 
CCL22 has been suggested to play a role in the trafficking of epidermal Langerhans 
cells at the inflammatory site (264) and in the formation of T cell-DC clusters in both 
inflamed skin and lymph nodes (265, 266).
In vivo approaches with D6 "A mice will be necessary to test the hypotesis that D6 
recognizing the majority of inflammatory CC chemokines may be important in the 
regulation of DC migration to lymph nodes via afferent lymphatics.
6.2.4 Is D6 expressed by leukocytes and is it able to dimerize with other 
chemokine receptors?
It will be necessary to further characterize D6 expression in leukocytes because its co­
expression with signalling chemokine receptors might be important for halting 
migrating cells following their arrival at an inflammatory site. This would enable 
leukocytes to accumulate at centres of chemokine production, and enable them to 
perform their functions efficiently, clear infectious agents, release anti-microbial 
compounds, further induce the inflammatory response, or promote resolution and 
healing. For dendritic cells and other antigen-presenting cells, pausing at inflammation 
sites could also enable more-complete exposure to the full range of antigens that can be 
phagocytosed and processed, ready for presentation to lymphocytes.
Data presented in this thesis suggest that D6 might also be able to function in a cell- 
autonomous manner to limit responses to chemokines. As shown in chapter 5 cells 
coexpressing CCR4 andD6 completely lost ability to migrate in response to CCL22: On 
the contrary, cell migration in response to CXCL12, a chemokine not scavenged by D6, 
acting on the endogenous CXCR4, was unaffected by D6 coexpression.
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Chapter 6-Summary and future plans
Future experiments have to be performed in order to understand if D6 forms dimers 
with CCR4 and if this is the mechanism responsible for the abolished functional 
response to CCR4 ligands in double transfectants.
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